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Production of radiopharmaceuticals intended for human use and research purposes is generally 
performed in well-equipped commercial or research facilities that usually have access to advanced 
equipment for the synthesis and quality control of radiopharmaceuticals. Nuclear Medicine 
departments are in most cases situated in hospitals. Radiopharmacies in these departments usually 
have limited space and equipment which necessitates careful consideration of suitable production 
methods. Optimization may include methods to simplify quality control procedures through the use 
of less sophisticated equipment and procedures.  
The purpose of this study was to demonstrate how to optimize production methods in an 
environment with limited resources using ubiquicidin labelled with gallium-68 as an example.  
The peptide ubiquicidin is currently investigated for localization of infections in patients using 
positron emission tomography (PET). Until recently, labelling ubiquicidin with gallium-68 was 
limited to a manual labelling method. Manual labelling methods are not recommended for the 
routine production of radiopharmaceuticals because of difficulty to comply with Good 
Manufacturing Practice (GMP). Manual labelling methods can also result in high radiation exposure 
to personnel. These disadvantages can be addressed by automation of production methods.  
The research conducted in this study shortly entails the following aspects: 
• Automation of a manual labelling method of ubiquicidin with gallium-68
• Optimization of the synthesis methods using radical scavengers
• In-depth comparison of the labelling characteristics of the manual method to that of the
automated methods
• Conducting a literature search into the toxicity of HEPES in humans and animals in order to
clarify its use as a buffering agent in the labelling of radiopharmaceuticals
Stellenbosch University https://scholar.sun.ac.za
iv 
• Investigating thin-layer chromatography as method to determine the radiochemical purity of 
gallium-68 ubiquicidin 
Two different automated synthesis methods were developed in this study. Optimization of the 
labelling methods was achieved by adding free-radical scavengers to reduce the formation of 
impurities. A comparison of the labelling characteristics of the manual labelling method with the 
automated methods showed that the results obtained with automated methods were more robust and 
repeatable.  
The literature search into the toxicity of HEPES showed that its toxicity in humans and animals may 
be overestimated by pharmacopoeias. The current limits applied by pharmacopoeias may be too 
strict. 
An evaluation of several thin-layer chromatography methods indicated that the method currently 
described in the literature may underestimate the presence of colloidal impurities in the final product. 
None of the other methods investigated in this study could distinguish the colloidal impurity from 
the labelled product. This aspect highlights the need for a final purification step to reduce the 
presence of colloidal impurities in the final product.  
The work presented in this study creates an important basis for optimization of production methods 
in a clinical environment. The study can further serve as a guideline to other nuclear medicine 







Produksie van radiofarmaseutika vir menslike gebruik en navorsing geskied oor die algemeen in 
goed toegeruste kommersiële- of navorsingsfasiliteite wat meestal oor gevorderde toerusting vir die 
sintese en gehaltebeheer van radiofarmaseutika beskik. Kerngeneeskunde-afdelings is oor die 
algemeen geleë in hospitale en hul radiofarmasie fasiliteite beskik dikwels slegs oor beperkte ruimte 
en toerusting wat deeglike oorwegingvan produksiemetodes noodsaak. Die optimiseringsproses kan 
vereenvoudiging van ingwikkelde gehaltebeheerprosedures insluit deur gebruik te maak van minder 
komplekse toerusting en prosedures. 
Die doel van hierdie studie was om met behulp van 'n produkvoorbeeld, nl ubiquicidin wat met 
gallium-68 gemerk word, ondersoek na die belangrikste aspekte van radiofarmaseutiese sinteses in 
'n betreklik eenvoudige opset te doen.  
Die peptied ubiquicidin word tans ondersoek om met die hulp van positron emissie tomografie (PET) 
infeksies in pasiënte op te spoor. Tot onlangs was die merking van ubiquicidin met gallium-68 
hoofsaaklik gebaseer op ’n handmerkingsmetode. Handmerkingsmetodes word nie aanbeveel vir 
roetine produksie van radiofarmaseutika nie; enersyds weens probleme om aan vereistes vir goeie 
vervaardigingspraktyk te kan voldoen en andersyds weens ‘n hoër stralingsdosis wat werknemers 
ontvang. Hierdie nadele kan grootliks oorbrug word deur die gebruik van modules wat die 
merkingsmetdoes outomatiseer.  
Die navorsing in hierdie studie behels kortliks die volgende aspekte: 
• Outomatisering van ‘n handmerkingsmetode om ubiquicidin 29-41 met gallium-68 te merk  
• Optimisering van die sintese prosedure deur die gebruik van vry-radikaalinhibeerders  




• Literatuurstudie na die toksisteit van HEPES in mense en diere om die gebruik daarvan as 
’n buffer in die vervaardging van radiofarmaseutika in perspektief te stel 
• Ondersoek van dunlaagchromatografiemetodes vir die bepaling van radiochemiese 
suiwerheid van gallium-68 ubiquicidin  
Twee verskillende tipes outomatiese sintesemetodes is vir die doeleindes van hierdie studie 
ontwikkel. Optimisering van die merkinsgsproses is bewerkstellig deur die gebruik van ten minste 
twee vry-radikaalinhibeerders om die vorming van ongewenste onsuiwerhede te beperk. ′n 
Vergelyking van die merkinsgeienskappe van die handmerkingsmetode teenoor die outomatiese 
metodes dui daarop dat die outomatiese merkingsmetodes meer robuust en herhaalbaar is.  
Die literatuurstudie na die gebruik van HEPES in mense en diere dui daarop dat die toksisiteit van 
HEPES in mense moontlik deur die farmakopieë oorskat word. Die grense wat tans deur die 
farmakopieë voorgestel word mag dalk te streng wees.  
Die evaluering van verskeie dunlaagchromatografiemetodes dui daarop dat die huidige metode wat 
in die literatuur beskryf word die teenwoordigheid van ’n kolloïdale onsuiwerheid in die finale 
produk onderskat. Al die ander metodes wat in hierdie studie ondersoek is kon nie hierdie 
onsuiwerheid van die gemerkte produk onderskei nie. Hierdie aspek beklemtoon die belangrikheid 
van van ’n suiweringstap in die merkingsprosedure om die teenwoordigheid kolloïdale onsuiwerheid 
in die finale produk te voorkom.  
Die werk wat in hierdie studie vervat word skep ’n belangrike grondslag vir toekomstige 
optimisering van produksiemetodes in ’n kliniese omgewing. Die studie kan verder ook deur ander 
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Chapter 1  
Introduction 
Background information 
Recent years have seen a drastic increase in the development of radiopharmaceuticals used for 
positron emission tomography (PET) [1, 2]. Despite this development of new radiopharmaceuticals 
for clinical use, not many are available in South Africa on a routine basis. Of all PET 
radiopharmaceuticals, 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) is probably the best known [3]. 
Fluorine-18’s half-life of 109 minutes makes this radionuclide attractive for regular use and it has 
been widely incorporated into various ligands for PET imaging [4, 5]. Other PET radionuclides such 
as carbon-11, nitrogen-13 and oxygen-15 are also used in the labelling of tracers for PET studies, 
but with half-lives of 20 minutes, 10 minutes and 2 minutes respectively, regular use in a clinical 
setting is limited. Use of these radionuclides further also requires an on-site cyclotron.  
Hospital radiopharmacies in South Africa are usually limited to the use of radiopharmaceuticals that 
are commercially available. This limits researchers in a clinical setting to perform research with only 
one or two commercially available radiopharmaceuticals. [18F]FDG is a typical example of such a 
radiopharmaceutical. It has been commercially available in South Africa since 2006 and has for 
almost a decade been the only commercially available radiopharmaceutical for PET imaging. 
[18F]sodium fluoride and [18F]fluoroethylcholine were only available on special request.  
The introduction of gallium-68 from germanium-68/gallium-68 (68Ge/68Ga) generators has launched 
a wider range of PET radiopharmaceuticals [6]. 68Ge/68Ga-generators provide a readily available 
supply of a positron emitting radionuclide that can be used in a hospital radiopharmacy without the 
need of an on-site cyclotron. The past few years have seen a dramatic increase in the labelling of 
tracers with gallium-68 [6–9]. Advances in several aspects in the design of 68Ge/68Ga-generators 
have made its application in a hospital radiopharmacy possible. These include development of 
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generator eluates that are suitable for labelling a number of compounds and the rapid development 
of peptides that can be labelled with gallium-68 using mono- and bifunctional chelators [10].  
Over the past few years, a number chelators have been developed which include non-macrocyclic 
and macrocyclic chelators [19-21]. Non-macrocyclic chelators include 
diethylenetriaminepentaacetic acid (DTPA), N’N-bis(2-hyroxybenzyl)ethylendiamin-N,N’-diacetic 
acid (HBED) and desferrioxamine (DFO). Macro-cyclic chelators include 1,4,7,10-tetra-
azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA), 1,4,7-tri-azacyclononane-1,4,7-triacetic acid 
(NOTA), 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA) and 1,4,7-
triazacyclononane phosphinic acid (TRAP). Both DTPA and DFO have the advantage that labelling 
can be performed at room temperature which is important when labelling heat sensitive molecules 
such as antibodies. DTPA labelling also requires less acidic labelling environments (pH = 5.0 – 7.4) 
[20]. DTPA has been extensively used as the chelator of choice in the labelling of indium-111 
pentetreotide while DFO derivatives can complex gallium-68 and zirconium-89 [20,24].  
DOTA is probably the best known macrocyclic bifunctional chelator and has been extensively used 
in the labelling of PET radiopharmaceuticals. More recently NOTA has gained more popularity in 
gallium-68 labelling of radiopharmaceuticals. Gallium-68 fits better into the smaller ring structure 
of NOTA. NOTA also has the advantage that labelling can be performed at room temperature. Some 
compounds may however require higher temperature to increase radiochemical yield (RCY). 
NODAGA is another important bifunctional chelator in gallium-68 labelling [20]. NODAGA has a 
glutaric arm instead of an acetic arm. The advantages of the hexadentate N3O3 structure is that it 
does not get destroyed as opposed to conjugated NOTA because it creates a space between the target 
molecule and chelator. Ubiquicidin 29-41 has also been successfully labelled with gallium-68 using 
a NODAGA chelator. [22]. The use of TRAP has also gained interest. TRAP can be labelled at room 
temperature and in a relatively short time (10 min.). It has also shown to be less affected by 
impurities present in gallium generators.  
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The development of automated synthesis modules that can be connected with 68Ge/68Ga-generators 
make it possible for hospital radiopharmacies to produce a PET radiopharmaceutical for clinical use 
[11–15]. Some modules also allow preparation of several different gallium-68 radiopharmaceuticals 
using the same synthesis unit. The Nuclear Medicine Division at Tygerberg Hospital currently 
produces [68Ga]Ga-DOTA-NOC and [68Ga]Ga-PSMA-11 using the same module. Automated 
modules can be pre-programmed to synthesise PET radiopharmaceuticals according to a standard 
method. The generator and synthesis module are placed in a hot cell, reducing radiation exposure to 
the operator. Hot cells with high-efficient particulate air (HEPA) filters also make it possible to 
produce radiopharmaceuticals under Good Manufacturing Practice (GMP) compliant conditions. 
Particular advantages of using automated synthesis modules are as follows: [16]  
• They help limiting radiation exposure to operators.  
• They ensure that radiopharmaceuticals can be prepared in a reproducible manner. 
• The modules are compact enough to be used in a hot cell. 
• The methods can be certified according to Good Manufacturing Practice to comply with 
local or international regulations for the production of radiopharmaceuticals. 
• Cassette-based systems have the further advantage that these can be supplied as sterile, 
pyrogen-free units, making compliance with GMP regulations easier. 
Automated synthesis modules on the other hand have the following disadvantages: 
• These modules and cassette systems are generally very expensive. 
• They require regular and planned preventative maintenance. 
• They require trained personnel for regular maintenance and repairs. 
If synthesis modules are equipped with software that allows the user to further customize the step-
by-step procedures of the module, new labelling or synthesis methods can be developed in-house. 
A typical module set-up for the synthesis of ubiquicidin 29-41 using a 68Ge/68Ga-generator is shown 
in addendum A. Synthesis modules are either equipped with fixed tubing systems, or they can make 
Stellenbosch University https://scholar.sun.ac.za
4 
use of cassette-based systems for the transfer of reagents during synthesis [21]. The use of fixed 
tubing has become less attractive due to difficulty to comply with GMP principles. Strict cleaning 
procedures, which have been extensively validated, are important to prove that the no residual 
contaminants from the previous synthesis are present at the start of the next synthesis. Fixed tubing 
can also not be sterilized prior to a synthesis to minimize the risk of bacterial and endotoxin 
contamination of the final product. Cassette-based systems on the other hand can be supplied as a 
sterile unit which has been manufactured according to GMP principles. These cassettes are typically 
manufactured as a single use item and are discarded prior to the start of the next synthesis. Nowadays 
it is possible to purchase fully GMP compliant synthesis kits that contain not only a sterile and 
pyrogen-free cassette, but also all the reagents and consumables required for the synthesis, 
manufactured under GMP conditions. 
 
Establishing an automated labelling method is usually based on a manual labelling method used in 
the initial development of the radiopharmaceutical. Conversion of a manual synthesis method to an 
automated method requires a thorough optimization process. Small quantities of radioactivity and 
precursors are normally used in the developmental phase to evaluate initial labelling characteristics 
such as radiochemical yield, chemical purity and stability. Also, the effects of adapting labelling 
parameters like pH, labelling temperature and heating times of the labelled product yield and purity 
may need to be assessed. Starting with low concentrations and gradually increasing the concentration 
of the precursor, the optimal precursor concentration for successful labelling is then identified. 
Radiolysis can cause formation of free radicals during the labelling process, which can damage the 
labelled compound. Optimizing a labelling method for a specific radiopharmaceutical may require 
the addition of radical scavengers to reduce the formation unwanted radiolytic impurities. PET 
radiopharmaceuticals such as fluorine-18 and gallium-68 are especially prone to radiolysis because 
of high radioactive quantities and specific activity [17, 18]. 
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Novel radiopharmaceuticals, when intended for clinical investigations, should ideally be produced 
using an automated synthesis module to ensure compliance to GMP. Translation of a manual 
synthesis to an automated one may pose certain challenges. It may be difficult to transfer small 
volumes of eluate and buffer accurately with an automated synthesis unit. Pre-purification of a 
generator eluate may be preferred when generators with known high levels of metal impurities are 
used for the radiosynthesis [10]. Some automated synthesis protocols offer this as a pre-set step. 
Manual methods often do not include a generator eluate pre-purification step. Schematic layouts of 
the manual and proposed automated labelling methods are illustrated in addenda B to D.  
Hospital radiopharmacies situated in Nuclear Medicine departments do not all have an extensive 
clean room suite and well-equipped analytical laboratories for the production and testing of 
radiopharmaceuticals. These facilities may be limited to basic equipment for relatively 
uncomplicated syntheses and quality control of the final product. Equipment usually includes 
standard instruments such a synthesis module, an HPLC instrument and a thin-layer chromatogram 
scanner to name a few. Access to more complex and expensive equipment like liquid 
chromatography - mass spectrometry (LC-MS) and Ultra Performance Liquid Chromatography  
(UPLC)may be less common.  
 
Purpose of study  
The purpose of this study was to investigate the most important factors that determine the successful 
optimization of production methods in a hospital radiopharmacy situated in a clinical setting with 






The objectives of this study were as follows:  
• To identify which aspects influence the process of converting a manual radiosynthesis 
method to an automated module based preparation of radiopharmaceuticals; 
• To identify the general aspects and radiolabelling parameters that may affect the quality of 
the radiopharmaceuticals;  
• To demonstrate how to optimize a production method in a hospital radiopharmacy with 
limited equipment; 
• To compare the labelling characteristics of radiopharmaceuticals prepared by an automated 
method with those prepared by a manual method; and 
• To evaluate the quality control procedures required for a newly synthesised product.  
 
Significance and motivation 
Labelling [68Ga]Ga-NOTA-UBI (29-41) with an automated synthesis module has not been described 
in the literature. The results obtained from this study can contribute significantly to the existing 
knowledge in the following way: 
• This study can serve as an example for the development of other automated methods for 
future radiopharmaceuticals. 
• It highlights the critical aspects involved in the quality control of products prepared by a 
new method.   
• It demonstrates how optimization of production can be achieved using limited facilities and 
equipment. 
• It can serve as a guideline for other Nuclear Medicine departments to successfully optimize 
production methods in their departments. 
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• It can lead to the expansion of current available radiopharmaceuticals in a routine clinical 
setting.  
This study focused on the development and optimization of two automated synthesis methods for 
labelling NOTA-UBI (29–41) (further referred to as NOTA-UBI) with gallium-68, one using 
fractional generator elution and the second method using a generator eluate pre-purification step. 
Optimizing the automated methods also took into consideration the choice of a buffer used for 
radiolabelling as well as an investigation into radical scavengers to reduce radiolysis. The use of 
thin-layer chromatography (TLC) and the need to optimize TLC methods are also discussed.  
 
Aim 
The aim of this study was to optimize the production method of a radiopharmaceutical in a hospital 
radiopharmacy using gallium-68 ubiquicidin as an example. It also included an investigation into 
thin-layer chromatography methods used to determine the radiochemical purity of gallium-68 
ubiquicidin.  
 
Delineation of the study  
The research presented in this study was limited to: 
• Using only gallium-68 from tin-oxide based iThemba LABS generators for the labelling 
procedure; 
• Optimization of a single radiopharmaceutical; and 






The research was designed around the following research questions:  
1. Can the development of in-house methods for an automated synthesis unit provide the 
foundation to expanding the current range of radiopharmaceuticals in a clinical setting? 
2. Which clinically acceptable radical scavengers can specifically improve the 
radiochemical purity of [68Ga]Ga-NOTA-UBI? 
3. Which labelling parameters are affected in the conversion of a manual radiosynthesis 
method to an automated one?   
4. What has been reported on the acute and chronic toxicity of HEPES to animals and 
humans and are the strict limits imposed on HEPES as a buffering agent in 
radiopharmaceutical manufacturing by the European and British Pharmacopoeias 
necessary? 
5. Can a suitable thin-layer chromatography method be identified that can be used to detect 
and quantify the presence of gallium-68 colloidal impurities in [68Ga]Ga-NOTA-UBI?  
 
Brief overview of the dissertation  
This dissertation has been compiled in a hybrid format. It comprises of published and unpublished 
articles and one chapter. Following this introductory chapter, the first research article describes the 
development and optimization of two automated synthesis methods (Chapter 2). The second 
research article compares the labelling characteristics of the automated synthesis methods to that of 
the manual method on which the automated method was based (Chapter 3). The third research article 
describes the effect of radical scavengers on the radiochemical purity of the in-house developed 
synthesis method (Chapter 4). A technical note presents the currently reported evidence on the acute 
and chronic toxicity of 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) in animals 
and humans and includes a critical debate on the very strict pharmacopoeial limits for this compound 
in radiopharmaceutical production (Chapter 5). Chapter 6 presents a series of experiments using 
Stellenbosch University https://scholar.sun.ac.za
9 
thin-layer chromatography techniques as quality control procedures to determine the presence of 
colloidal gallium-68 impurities that may be present in [68Ga]Ga-NOTA-UBI 29-41 preparations. 
Chapter 7 provides an overall summary of the achieved results, the study limitations and 
recommendations as well as the study conclusion. 
Note that the articles and references are presented in the format prescribed by the respective journals’ 
guidelines.  
All studies were approved by the Stellenbosch University Health Research Ethics Committee 
(S15/10/235). This research is purely based on experimental laboratory work that does not involve 
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Chapter 2  
Development of an automated synthesis method for  
68Ga-labelled ubiquicidin 29-41 
 
Rationale for research covered in this chapter 
The use of automated synthesis modules has in recent years become an important aspect of the 
production of radiopharmaceuticals. Such modules make it easier for production facilities to 
comply with GMP guidelines. The automated labelling method is usually based on an optimized 
manual method used during the development phase of the radiopharmaceutical. The article below 
describes the development of  three automated synthesis methods for the labelling of gallium-68 
ubiquicidin using a Scintomics GRP synthesis module.  
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Published methods for radiolabelling of 1,4,7-triazacyclononane-1,4,7-triacetic acid ubiquicidin 
(NOTA-UBI) 29-41 to date describe manual or kit-based procedures. The purpose of this study was 
to develop an automated synthesis method for the synthesis of [68Ga]Ga-NOTA-UBI. NOTA-UBI 
was successfully labelled with gallium-68 using the three different automated procedures. The use 
of radical scavengers to improve radiochemical purity is also discussed. The automated procedures 
showed a high degree of robustness and repeatability. The validated automated synthesis protocols 
using a Scintomics GRP Module will contribute to provide GMP-compliant [68Ga]Ga-NOTA-UBI 
for clinical infection imaging. 
 
Introduction 
Bacterial infections are a major contributor to the increasing costs of health care. Early, accurate 
detection of such infections may improve outcome and therefore reduce the costs associated with 
bacterial infection. Early detection and localisation also plays an important role in patient 
management as the process of identifying the site of infection is often difficult and time consuming 
which contributes to health care costs [1]. 
In order to make an accurate diagnosis, a number of steps are followed which include taking a 
detailed patient history and physical examinations, followed by a variety of laboratory tests such as 
erythrocyte sedimentation rate and C-reactive protein measurements. Various imaging modalities 
are utilised to localise the site of infection. These modalities include X-rays, ultrasonography, 
magnetic resonance imaging and computed tomography.  
Nuclear imaging techniques to localise infections date back several decades. The use of gallium-67 
citrate has been extensively described for imaging of infections [2–4]. Indium-111 or technetium-
99m (99mTc) labelled leucocytes and 99mTc-labelled ciprofloxacin with better imaging qualities than 
gallium-67 made them more attractive as infection imaging agents [2, 5, 6]. To date, imaging in 
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vitro labelled white blood cells with technetium-99m or indium-111 is still considered the gold 
standard for detection of peripheral infection [5].  
The dawn of positron emission tomography (PET) has seen a rise in the need for tracers that can be 
labelled with positron emitters such as fluorine-18 (18F) or gallium-68 (68Ga). Labelling tracers with 
positron emitters offers the advantage of imaging with a higher spatial resolution than conventional 
single photon emission tomography (SPECT).  
2-Deoxy-2-[18F]fluoroglucose, ([18F]FDG) has been widely used in the imaging of bacterial 
infections [7–9]. The low specificity of [18F]FDG has been described as a major limitation. It further 
cannot distinguish between infections and sterile inflammatory processes, malignancies and the 
normal wound healing process [10,11]. These limitations of [18F]FDG as the current ideal infection 
imaging agent have led to a continued quest for a PET imaging agent that will not only allow specific 
detection of bacterial infections, but also be able to distinguish between sterile inflammation and 
bacterial infections. 
Theory 
Ubiquicidin (UBI) is a human antimicrobial peptide and synthetic derivatives of this peptide have 
been suggested as a possible agents for imaging infections [12, 13]. The UBI fragment 29-41 
(TGRAKRRMQYNRR) has been successfully labelled with technetium-99m [14, 15]. As 
mentioned previously, better spatial resolution can be obtained using PET radionuclides such as 
gallium-68, as opposed to technetium-99m, a conventional SPECT radionuclide. Besides the 
favourable imaging qualities of gallium-68, a physical half-life of 67.71 min coincides well with the 
biokinetics of low molecular weight peptide radiopharmaceuticals [16].   
Since the introduction of cost-efficient 68Ge/68Ga-generators, labelling of various peptides such as 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaceticacid–1-NaI3-octreotide (DOTA-NOC), 1,4,7, 
10-tetraazacyclododecane-1,4,7,10-tetraaceticacid- 1-Tyr3-octreotate (DOTA-TATE), and the 
peptidomimetic inhibitor of prostate specific membrane antigen (PSMA) with gallium-68 has been 
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well described [17-19]. 68Ge/68Ga-generators have the advantage of a PET radionuclide being 
readily available as opposed to cyclotron produced radionuclides such as fluorine-18 and carbon-
11. Radiolabelling of UBI 29-41 fragments with gallium-68 has been performed utilising bi-
functional chelators like 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA). This 68Ga-labelled 
radiopharmaceutical is currently being investigated as a potential infection imaging agent [20]. 
Ebenhan and co-workers also indicate that selective binding to bacterial cells is not compromised 
by the labelling procedure.  
Published methods for radiolabelling of UBI initially only described manual processes [14, 15, 21, 
22]. More recently, kit-based labelling methods have also been published [23, 24]. Kit based 
methods do not require expensive synthesis modules but do not address the possible risk of a higher 
radiation exposure to operators. Automation of labelling procedures has the benefit of reducing 
radiation exposure to personnel and due to standardization, makes these procedures more reliably 
compliant with good manufacturing practices (GMP) [25].   
The automated labelling methods introduced by this study do not require HPLC purification of the 





All steps in the automated labelling procedure were performed using a Scintomics GRP automated 
synthesis module (Scintomics, Germany). Freeze-dried NOTA-UBI (Shanghai, China or ABX, 
Germany) was dissolved in Millipore water (18.5Ω) and subdivided in 50 µl aliquots (1 µg/µl) and 
frozen at - 20°C.  50 µg of frozen NOTA-UBI was used for each of the labelling methods, except in 
our study investigating scavengers, where 100 µg NOTA-UBI was used to improve radioyield of 
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the cationic purification method. 68Ga was obtained by eluting a 68Ge/68Ga-generator (iThemba 
LABS, South Africa) using 0.6 M HCl (ABX, Germany). C18 Sep-Pak (tC-short) cartridges 
(Waters, USA) were pre-conditioned on the synthesis module at the start of the synthesis using 5 ml 
HPLC-grade ethanol (Merck, USA). 1.5 M 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid 
(HEPES) buffer (pH = 5.0) and PS-H+ cartridges as well as GMP-prepared kits for the Scintomics 
synthesis module were obtained from ABX, Germany, and sodium acetate trihydrate from 
Honeywell Riedel-de-Haën, Germany. Sodium chloride 0.9% (B.Braun, South Africa) and 
pharmaceutical grade ethanol (Merck, USA) were used to prepare the ethanol/saline (50% v/v) 
solution. Ultrapure water was freshly prepared with a Milli-Q water purification system (Millipore, 
USA). Ascorbic acid (North East Pharmaceutical Group, South Africa), genticic acid (Merck, USA) 
and pharmaceutical grade ethanol (Merck, USA) were tested as radical scavengers. Ammonium 
formate (Kimix, South Africa) was used to prepare a 1.0 M ammonium formate solution. HPLC 
analyses were carried out using HPLC-grade acetonitrile (Merck, USA) and trifluoroacetic acid 
(Sigma Aldrich, Germany). 
Reference manual labelling 
Certified 10 ml glass vials, prepared with a solution containing 25 µg NOTA-UBI per vial, were 
freeze-dried overnight and stored at - 20 °C until the day of radiosynthesis. Manual radiosyntheses 
(n = 14) were performed according to a previously published method to create a reference dataset 
[21]. Briefly, the manual method consisted of fractional eluting a 68Ge/68Ga-generator with 0.6 M 
HCl. Sodium acetate – buffered 68Ga was added to 50 nM NOTA-UBI 29-41and incubated at 90°C 
for 15 minutes. The radiolabelled product was purified using a C18 SEP PAK cartridge and filtered 
through a 0.22µm sterile filter. 
 
Automated Method 1) Fractional generator elution and pH adjustment with HEPES 
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The generator was eluted in 2.0 ml fractions. The first 2.0 ml fraction of the elution was discarded 
to the waste container. The second fraction of 2.0 ml was used for the labelling procedure. The 68Ga 
was slowly added to a volume of 1.5 ml of 1.5 M HEPES buffer (pH = 5.0) to render a buffered 
eluate mixture with a pH between 3.5 and 4.0. The buffered 68Ga-eluate mixture was then slowly 
added to the reaction vessel containing 50 µg NOTA-UBI. The concentration of NOTA-UBI in this 
mixture was 14.3 µg/ml.  This mixture was heated for 10 minutes at 90°C, cooled for one minute 
and purified using a C18 SEP-PAK cartridge. 68Ga-labelled NOTA-UBI was desorbed from the C18 
cartridge using 2 ml ethanol/saline (50% v/v), and passed through a 0.2 µm sterile filter into a sterile 
vial. The final product was further diluted to 15 ml with phosphate buffered saline (PBS).  
 
Automated Method 2) Fractional generator elution and pH adjustment with sodium acetate  
68Ga-chloride was fractionally eluted with 0.6 M HCl as described earlier, followed by the slow 
addition of the 68Ga-eluate to a volume of 2.8 ml of 1.0 M sodium acetate solution (pH = 8.5) to 
render a buffered eluate mixture to a pH level between 3.5 and 4.0. The buffered 68Ga was mixed 
with 50 µg NOTA-UBI providing a concentration of 10.4 µg NOTA-UBI per ml in the reaction 
mixture. The synthesis continued further as described in method 1 above. 
 
Automated Method 3) Eluate processing by cationic purification and radiolabelling 
The cationic eluate processing method was based on a method published by Martin et al. [26]. 
Briefly, the 68Ge/68Ga-generator was eluted with 10 ml 0.6 M HCl and diluted to 18 ml with Milli-
Q water. The diluted HCl solution was then slowly passed over a PS-H+ cartridge (ABX, Germany) 
to retain most of the 68Ga. Purified 68Ga was recovered from the PS-H+ cartridge using 1.5 ml 5.0 M 
NaCl solution which was then transferred into the reaction vessel which contained 50 µg NOTA-
UBI in 1.3 ml of 1.0 M acetate solution. The concentration of NOTA-UBI in this reaction mixture 




Instant thin-layer chromatography (ITLC) 
Instant thin layer chromatography was performed as described by Breeman et al. [27] using a glass 
microfiber chromatography medium impregnated with silica gel (ITLC-SG, Varian, USA). The 
mobile phase consisted of 0.1 M sodium citrate (pH = 5.0).  Measurement of radioactivity was 
performed using a Curiementor PTW dose calibrator (PTW, Germany) by way of measuring the 
ITLC strip cut into distinct pieces, or running the entire ITLC strip on a radio-chromatographic 
scanner (Lablogic, United Kingdom).  
HPLC analyses 
HPLC analysis was initially performed using Waters HPLC system (Waters, USA). A sample of the 
labelled product was analysed by HPLC using a variable wavelength PDA UV-detector (Waters, 
USA) and a Raytest gamma detector (Raytest, Germany). The mobile phase (v/v) for the isocratic 
HPLC analysis was 15% acetonitrile, 85% ultrapure water, supplemented with 0.1% of 
trifluoroacetic acid (TFA). The flow rate was set at 1 ml/min. A Waters C18 Symmetry analytical 
column (4.6 x 250mm x 4.6 mm x 5μm, Waters, USA) was used as the stationary phase for all 
analyses. 
Subsequent analyses of the labelled product were done using a Schimadzu, Nexera XR HPLC 
system (Shimadzu, Japan) with a variable wavelength PDA UV-detector and a Raytest gamma 
detector (Raytest, Germany). The mobile phase (v/v) for the gradient HPLC analyses was 0.1% TFA 
in ultrapure water and 0.1% TFA in acetonitrile. The flow rate was set at 1 ml/min. A Waters C18 
column (Waters, USA) was used as the stationary phase for all analyses. [68Ga]Ga-NOTA-UBI 
eluted at 10.0 - 11.0 min on radio-HPLC, while free gallium-68 eluted at 3.0 – 4.0 minutes. The 
retention time of free gallium-68 was confirmed by HPLC analysis using a buffered 68Ga-eluate 
solution with a pH of 3.5 – 4.0. Using a flow rate of 2 ml/min and adjusting the gradient time of the 
analysis to shorten the analysis was also investigated.  
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Radionuclidic identity  
A sample of [68Ga]Ga-NOTA-UBI was measured in a dose calibrator and the radioactivity recorded 




Germanium-68 (68Ge) breakthrough was routinely measured in each of the labelled products using 
a Curiementor PTW dose calibrator (PTW, Germany). This was performed 48 hours post synthesis 
when the 68Ga decay was >10 half-lives. 68Ge was measured indirectly by way of detection of 68Ga 
produced only by leaked 68Ge in the sample [28]. 
 
Determination of HEPES content 
The European Pharmacopoeia (Ph. Eur.) describes an ITLC method to be used for the determination 
of HEPES content following syntheses with 68Ga where HEPES is used as a buffering agent [29]. 
The limit for HEPES is 200 µg/V where V is the maximum injected dose in milliliters. In our 
institution this limit was calculated to be 13.3 µg/ml. This method uses silica-gel ITLC strips as the 
stationary phase and a mobile phase of acetonitrile (Merck, USA) and Millipore water (80:20 v/v). 
Fifteen microliters (15 µl) of an in-house prepared HEPES reference solution (13.3 µg/ml) and 
[68Ga]Ga-NOTA-UBI (test solution) were applied at the origin of the TLC plate. The mobile phase 
was allowed to migrate to two thirds of the height of the strip and the strip then removed and allowed 
to dry. The dried strip was developed in a chamber containing iodine crystals. The intensity of the 





Further quality control measures 
In addition, the following tests were performed after each radiosynthesis to justify the product 
validity for human administration and to comply with specifications for batch release of 
radiopharmaceuticals: 
Residual radioactivity on PS-H+ cartridges was measured in a Curiementor PTW dose calibrator 
(PTW, Germany). Residual radioactivity on the C18 cartridge at end of synthesis (EOS) was also 
measured in all instances irrespective of the labelling method used. 
The pH of 68Ga-labelled NOTA-UBI was tested with pH indicator strips with a range of 5.0 – 10.0. 
(Merck, USA). The pH value was read in increments of 0.5. Integrity of the sterilisation filter was 
tested using a Millipore pressure gauge (Millipore, USA).  
During synthesis, labelled [68Ga]Ga-NOTA-UBI was desorbed from the SEP-PAK C18 cartridge 
using a mixture of 1 ml ethanol and 1 ml 0.9 % sodium chloride (50% v/v). The final volume of the 
labelled compound was programmatically set to 15 ml using the Scintomics software. The ethanol 




Sterility testing was performed by the National Health Laboratory Services at Tygerberg Hospital. 
A peptone nutrient broth, Brucella agar plates and Sabouraud dextrose agar plates were utilized to 
test for aerobic, anaerobic organisms and fungi respectively. Briefly, a sample from test the solution 
was withdrawn and each culture media inoculated using aseptic technique. The peptone nutrient 
broth and Brucella agar plates were incubated at 35 °C for a minimum of 5 days while Sabouraud 




Bacterial endotoxin spectrophotometry 
Rapid endotoxin unit (EU) spectrophotometry (SPM) was performed using the Endosafe portable 
testing system (PTS) (Charles Rivers, USA) [30]. The analysis of the radiopharmaceutical samples 
was deemed acceptable if the recorded values were within the following specification: sample 
reading: < 10 EU/ml, sample coefficient of variance: < 25%, spike coefficient of variance: < 25%, 
and recovery: 50 – 200%  
Methods 1 - 3 were subjected to three full scale validation studies (see methods above) using our in-
house release criteria (Table 2.1) for releasing radiopharmaceuticals for human use. Validation 
studies were performed using sterile cassettes (ABX, Germany) and reagents which included a 
phosphate buffered saline solution, ethanol, water for injection and 5.0 M NaCl solution (ABX, 
Germany). The 50:50 (v/v) ethanol/saline mixture was prepared fresh in-house and sterilised using 




Table 2.1 Summary of quality control procedures and release criteria 
Quality control procedure Release criteria Method 
Visual appearance Clear, colourless, particle free Visual inspection 
Radiochemical purity ≥ 95% [68Ga]Ga-NOTA-UBI ITLC / HPLC 
Radionuclidic identity (half-life) 63 – 73 minutes Dose calibrator 
pH of final product 4.0 – 8.0 pH strips 
Bacterial endotoxin  < 10 EU/ml Endosafe PTS SPM 
Residual ethanol content < 10%  v/v Direct calculation 
Sterile product filtration  ≥ 3.45 bar Filter integrity test 
Bacterial growth testing sterile (pass) Broth testing 
Germanium breakthrough <0.001 % Dose calibrator 
Chemical purity  [68Ga]Ga-NOTA UBI peak at  
retention time = 10-11 min 
HPLC 
Notes: EU = Endotoxin units, PTS = portable endotoxin system, SPM = spectrophotometer 
 
Results and discussion 
The manual labelling method described by Ebenhan et al. formed the basis for our in-house 
automated labelling procedure [20]. This method was considered too rigid to make a seamless 
translation to an automated module. The main challenges were the small total labelling volume and 
the concentrations of reagents, the peptide molarity and type of buffer. In addition, a suitable cation-
exchange based generator eluate pre-processing method has not been investigated. This study set 
out to develop a robust radiosynthesis solution applicable to automated modules. A full scale 
generator elution requires 10 ml 0.6 M HCl to yield all the elutable 68Ga-activity, however, based 
on the nature of the generator elution profile, 84 - 92 % of that activity can be collected in 2 - 3 ml 
which also leads to a concentrated 68Ga-eluate.  
The relatively small volume (± 550 µl) of 2.5 M sodium acetate used during the manual procedure 
for pH adjustment was too small to be effectively incorporated into an automated synthesis method 
(see Table 2.2 for a comparison of manual and automated methods). Sodium acetate (1.0 M) and 
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HEPES (1.5 M) were considered to be applicable buffering agents to adjust the pH of the labelling 
mixture. Sodium acetate has been widely described as a buffering agent in the synthesis of  68Ga-
labelled peptides [31–34] and is considered the buffer of choice because of its safe biological profile 
[35].  Alternately, we opted to investigate HEPES buffer for the reasons described above. HEPES is 
a zwitterionic buffer with a pKa1 and pKa2 of 3.0 and 7.55 respectively and belongs the Good’s 
group of buffers used in biological research [36]. The pKa value of sodium acetate on the other hand 
is 4.76 [37], thus, HEPES is expected to have a better buffering capacity than sodium acetate at a 
pH range of 3.0 – 4.0. Table 2.2 presents a comparison of the manual method with the three 
















Generator age during study (d) 120 – 244 145 - 181 112 – 180 145 - 153 
Type of generator elution FE FE FE Full scale 
Volume: 68Ga-activity (ml) 1.0 2.0 2.0 10 
Buffering solution 2.5 M NaOAc  1.5 M HEPES 1.0 M NaOAc 1.0 M NaOAc 
Volume of buffer used (µl) 278 1500 2800 1300 
pH of labelling mixture 3.5 - 4.0 3.5 - 4.0 3.5 – 4.0 3.5 – 4.0 
NOTA-UBI concentration / 
labelling (µg/ml) 
19.6 14.3 10.4 17.9 
Heating time (min) 10-15 10 10 10 
Heating temperature (°C) 90 90 90 90 
Radiochemical yield   65.5 ± 22.6 83.4 ± 6.7  71.8 ± 3.5  78.9 ± 3.6 
Radioynthesis time (min) 31 ± 7 38 ± 2 38 ± 2 44 ± 2 
% Average radiochemical purity 97.1 ± 1.9 99.6 ± 0.2  99.6 ± 0.5  99.0 ± 1.7  
Activity yield  (MBq) 473 ± 234 616 ± 21 537 ± 52 514 ± 24 
Molar activity (MBq/nmol) 20.4 ± 11.4 26.5 ± 0.8 21.3 ± 2.0 20.6 ± 0.9 
Activity retained on C18 at EOS 
(MBq)   
65.9 ± 55.9 6.5 ± 3.1 9.8 ± 3.8 31.5 ± 8.3 
Residual activity on P-SH+ 
cartridge at EOS (MBq) 
- - - 79.3 ± 10.4  
Retained C18 activity (%) 10.0 ± 8.9 0.59 ± 0.3 1.3 ± 0.4 6.2 ± 1.6 
Notes: EOS = End of synthesis, FE = fractional elution  
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Fractional elution method using HEPES buffer 
Six successful automated syntheses using 1.5 M HEPES buffer were performed to prove that a 
satisfactory labelling can also be obtained using HEPES buffer. During the development of the 
automated procedure various volumes of eluate and buffer solution were tested to determine 
optimum labelling conditions.  Eluate and buffer volumes of 1000 – 2000 µl and 1200 – 1600 µl 
were respectively used. Routine syntheses were carried out using an eluate volume of 2000 µl 
buffered with 1500 µl 1.5 M HEPES. 
Radiolabelling was carried out using a Scintomics automated synthesis module. The average 
radiochemical yield was 83.4 ± 6.7% (n = 6). The average radiochemical purity was 99.6 ± 0.2 % 
(n = 6) using a thin-layer chromatographic method. Total synthesis time was 39 - 41 minutes which 
included pre-conditioning of the C18 SEP-PAK cartridge, fractional elution and a final rinsing of 
the cassette tubing with water to flush away residual radioactivity from the cassette.  
With HPLC analysis using the gradient method as described above, we were able to successfully 
distinguish between free gallium-68 (3.0 minutes) and 68Ga-labelled NOTA-UBI (10.0 – 11.0 
minutes). The presence of a radiochemical impurity due to radiolysis was observed at retention time 





Figure 2.1a Radio HLPC of [68Ga]Ga-NOTA-UBI using fractional elution and HEPES 
buffer 
 
Results for the determination of the HEPES content in the final radiolabelled product indicated a 
HEPES content higher than the Ph. Eur/BP limit. The reason for this observation is not fully 
understood as HEPES is routinely used as a buffer in our institution in the labelling of [68Ga]Ga- 
DOTA-NOC and PSMA (data not shown). The HEPES content in the latter two radiolabelled 
products does not exceed our in-house specification of 13.3 µg/ml. The unexpected high HEPES 
content in [68Ga]Ga-NOTA-UBI necessitated the investigation of an alternative buffer such as 
sodium acetate. An automated labelling method using HEPES was therefore not further developed 
and validated. 
 
Fractional elution method using 1.0 M sodium acetate solution 
The same method used in the fractional elution method with HEPES was used but HEPES was 
replaced with a sodium acetate solution. The volume of sodium acetate buffer tested during the 
developmental phase ranged from 2000 – 3000 µl. Development of this method was based on a 
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fractional elution method where the second eluate fraction of 2000 µl was buffered with   2800 µl 
1.0 M sodium acetate solution.  
Radiolabelling was carried out as described above. The average radiochemical yield was 71.8 ± 3.5 
% (n = 10). The average radiochemical purity was 99.6 ± 0.5 % (n = 9) using a thin-layer 
chromatographic method. Total synthesis time was 39 - 41 minutes which included pre-conditioning 
of the C18 SEP-Pak cartridge, fractional elution steps and final rinsing of cassette tubing.  
A sample from the labelled [68Ga]Ga-NOTA-UBI was taken for HPLC analysis. Using the gradient 
method as described above, 68Ga-labelled NOTA-UBI eluted at 10 – 11 minutes as shown in the 
Figure 2.1b. The presence of a radiochemical impurity due to radiolysis was again observed at 
retention time ± 9 minutes. 
 
Figure 2.1b Radio-HPLC of [68Ga]Ga-NOTA-UBI using fractional elution and 




Fractional elution of the 68Ge-68/68Ga-generator, however, does not guarantee that all metal 
impurities are removed from the eluate during the first elution. Cationic or anionic pre-purification 
of generator eluates are therefore suggested, especially in 68Ge/68Ga-generators that have shown a 
greater tendency for higher levels of metal contaminants to elute from the generator column. This is 
considered an important factor, especially when 68Ge/68Ga-generators are eluted in a large volume 
and at a low pH [38]. The presence of metal impurities has a detrimental effect on the labelling 
process.  
 
Cationic pre-purification method 
A cationic pre-purification method using a PS-H+ cartridge and 1.0 M sodium acetate solution as a 
buffering agent was further developed. The advantages of cationic pre-purification of the 68Ga- 
eluate, using a PS-H+ cartridge eluted with a solution of 5.0 M sodium chloride, have been well 
described by Martin et al [26]. 
The development phase consisted of testing sodium acetate volumes of 1200 – 2100 µl to adjust the 
pH of the labelling solution to a required pH of 3.5 – 4.0. A volume of 1300 µl sodium acetate 
solution was used during routine syntheses.  
Radiolabelling was carried out as described above. The average radiochemical yield was 78.9% (n 
= 7). The average radiochemical purity was 99.0% (n = 7) using a thin-layer chromatographic 
method. Total synthesis time was 43 - 45 minutes which included pre-conditioning of the C18 SEP-
PAK cartridge, generator elution, as well as final rinsing of the cassette tubing. 
Using HPLC analysis, 68Ga-labelled NOTA-UBI eluted at 10 – 11 minutes as shown in Figure 2c. 





Figure 2.1c Radio-HPLC of [68Ga]Ga-NOTA-UBI using sodium acetate buffer and 
cationic pre-purified eluate 
 
Total HPLC analysis time was 40 minutes. Increasing the flow rate to 2 ml/min and adjusting the 
gradient time of the analysis resulted in a shorter analyses time of 25 minutes. This shorter method 
could be successfully used for routine analyses. Using the shorter method, non-chelated gallium-68 
eluted at 1-2 minutes while 68Ga-labelled NOTA-UBI eluted at 6 – 7 minutes.  
 
Radical scavengers use to reduce radiochemical impurities during synthesis 
Our labelling methods described above, resulted in a significant formation of a radiolysis impurity 
which was observed on radio-HPLC (see Figures 2.2 a - c). For this reason, it was deemed necessary 
to investigate the use of radical scavengers to improve radiochemical purity. The use of scavengers 
has been well described [39, 40]. 
Scavengers investigated for labelling methods 2 and 3 included ascorbic acid, genticic acid and 
ethanol. For reasons described above, the used of a scavenger in method 1 was not investigated.   
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Results from our study, using scavengers listed above, concluded that for the fractional elution 
method (method 2), ascorbic acid 1.4% was effective in reducing the impurity. Our results further 
improved when sodium acetate buffer was replaced with 1.0 M ammonium formate solution.  Using 
this combination of buffer and scavenger, a radiochemical purity of ≥ 95% was achieved on radio-
HPLC (n = 3). Formic acid is currently used as part of a buffering solution in the preparation of  
FDA approved NETSPOT® [41].  
For method 3, 1.0 M sodium acetate buffer (supplemented with concentrated hydrochloric acid to a 
pH of 4.5) was used. This buffer together with a combination of 350 µl of a 1.4% ascorbic acid 
solution and 170 µl ethanol (5% of total labelling mixture volume), reduced the radiolysis impurity 
significantly, increasing the radiochemical purity to ≥ 95% on radio-HPLC (n = 3).  





Table 2.3 Automated method using radical scavengers 
 Method 2 
(n = 3) 
Method 3 
(n = 3) 
Type of generator elution FE Full scale 
Buffering solution 1.0 M ammonium formate 1.0 M NaOAc (pH = 4.5) 
Volume of buffer used (µl) 2000 1500 
Scavenger volume used (µl) 350 µl 1.4% ascorbic acid 
170 µl ethanol 




Radiochemical yield 63.2 ± 1.5 57.3 ± 3.8 
% average radiochemical purity (TLC) 98.9 ± 0.3 99.31 ±0.1 
% average radiochemical purity  
(radio-HPLC) 
96.4 ± 0.9 97.3 ± 0.5 
Activity yield (MBq) 690 ± 22 580 ± 99 
Molar activity (MBq/nmol) 27.6 ± 0.9 11.4 ± 1.9 
Activity retained on C18 at EOS (MBQ) 11.4 ± 10.0 14.2 ± 7.4 
Residual activity on P-SH+ cartridge at EOS 
(MBq) 
- 129 ± 30 
Retained C18 activity 1.6 ± 1.4 2.5 ± 1.5 
Notes: EOS = End of synthesis, FE = fractional elution 
 
Radio-HPLC chromatograms of labelling methods 2 and 3 which include the addition of one or 
more scavenger, are presented in Figure 2.2a – b below. These chromatograms clearly show the 
improvement in radiochemical purity when scavengers are incorporated into the labelling methods. 





Figure 2.2a3Radio-HPLC of [68Ga]Ga-NOTA-UBI using fractional elution and 
ammonium formate buffer with the addition of ascorbic acid 
 
 
Figure 2.2b4Radio-HPLC of [68Ga]Ga-NOTA-UBI using cationic purification 





Instant thin-layer chromatography 
Labelled [68Ga]Ga-NOTA-UBI was retained at the origin (Rf = 0 – 0.1) on the ITLC strip, while 
any free 68Ga migrated with the solvent front (Rf = 0.8 - 1.0). No significant differences were found 
when the radiochemical purity was determined using the dose calibrator or the radio-
chromatographic scanner. Figure 2.3 illustrates an example of a typical readout from a [68Ga]Ga-
NOTA-UBI ITLC analysis. Note a wider region of interest was chosen for region 1 to compare this 
method with a “cut and measure” method using a dose calibrator.  
 
 
Figure 2.35ITLC analysis of 68Ga-NOTA UBI. Region 1 is [68Ga[Ga-NOTA-UBI and 
region 2 is free gallium-68.  
 
Germanium breakthrough 
Our institution uses an iThemba LABS 68Ge/68Ga-generator which is routinely eluted with 0.6 M 
HCl. This generator has previously shown significant 68Ge breakthrough [42]. Three different 
generators with varying ages were used during the development of these automated synthesis 
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methods. Germanium breakthrough was observed in the eluates of one of the generators used in the 
development of the automated labelling methods. It was therefore deemed necessary to determine 
germanium breakthrough in the final product for each of the automated labelling methods.  
No germanium breakthrough was observed in any of the final products synthesised with each of the 
different labelling methods. These results further confirmed that, should germanium be present in 
eluates, it is sufficiently removed during the synthesis process. 
 
NOTA-UBI concentration of labelling mixture (µl/ml) 
The concentration of NOTA-UBI in the final labelling mixture of all three labelling methods varied 
from 14.3 – 17.9 µg/ml. In the study using radical scavengers, the concentration NOTA - UBI varied 
from 11.2 – 27 µg/ml.   Results indicated that a higher concentration of NOTA-UBI in the final 
labelling mixture did not necessarily result in a better yield, irrespective of the labelling method and 
buffer used.  
 
Molar activity of labelled product 
The molar activity of the [68Ga]Ga-NOTA-UBI was calculated for each of the three labelling 
methods. The fractional elution method using HEPES as buffer resulted in the highest molar activity 
(26.5 ± 0.8 MBq/nmol) compared to the molar activity obtained with the fractional elution (21.3 ± 
2.0 MBq/nmol) and cationic pre-purification (20.6 ± 0.9 MBq/nmol) methods using sodium acetate 
as buffer.  
In our study that investigated the use of scavengers, the highest molar activity (27.6 ± 0.9 
MBq/nmol) was achieved with the fractional elution method using 1.0 M ammonium formate as 
buffer and ascorbic acid as a scavenger. The molar activity of the cationic purification method using 
a combination of ascorbic acid and ethanol as scavengers and buffered sodium acetate was 11.4 
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MBq/nmol. This was expected as 100 µg of NOTA-UBI peptide was used for the synthesis. This 
higher amount of peptide is not expected to produce any toxicity in humans. The study by Akhtar et 
al. intravenously injected a dose of 400 mg of ubiquicidin 29-41 labelled with 99mTc,  without any 
side effects [12]. 
 
Validation of automated synthesis method  
Three validation studies were performed on each of the automated labelling methods. Labelling of 
NOTA-UBI with 68Ga using a fractional elution method has been successfully developed, tested and 
validated. The final product fulfilled all our in-house criteria for GMP release.  
Labelling of NOTA-UBI with 68Ga using a cationic pre-purification method has also been 
successfully developed, tested and validated. The final product fulfilled all our in-house criteria for 
GMP release. 
 
Choice of automated labelling method 
68Ga labelling of NOTA-UBI can be successfully performed using both fractional elution and 
cationic purification automated methods.  The fractional elution method using HEPES as buffering 
agent method gave the best radiochemical yield. The fractional elution method using HEPES as 
buffer resulted in the highest molar activity (26.5 MBq/nmol). Velikyan also reported a higher molar 
activity obtained when using HEPES buffer in the labelling of DOTA-NOC with 68Ga [33]. 
Unfortunately, this study also indicated that HEPES is not a suitable buffer for the labelling of 
NOTA-UBI as the HEPES content in the final product exceeded the limits published in the Ph. Eur. 
and BP.  All three automated labelling methods resulted in radiochemical yields in excess of 71%. 
Radiochemical yields for the study investigating the use of scavengers for method 2 and 3, resulted 
in an average radiochemical yield of 60%. The radiochemical purity on TLC for all three automated 
labelling methods, including the study which investigated radical scavengers, was consistently more 
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than 98%. As previously mentioned, fractional elution does not guarantee that all metal impurities 
will be removed in the first fraction and these metal impurities may result in sub-optimal labelling 
conditions. Pre-purification with cationic exchange cartridges such as a  
PS-H+ cartridge have been widely used to purify generator eluates from metal impurities. The choice 
of an automated labelling method will therefore heavily depend on the characteristics of the 
generator used during the labelling. To reduce the presence of impurities due to radiolysis, radical 
scavengers such as ascorbic acid and ethanol were successfully incorporated in labelling method 2 
and 3, resulting in an increase in radiochemical purity using radio-HPLC.  
More recently, kit-based labelling of [68Ga]Ga-NOTA-UBI 29-41 has also been described. Kit-based 
labelling of radiopharmaceuticals has the advantage that it does not require an expensive synthesis 
module for the labelling process. However, the need for pre-purification of generator eluates and the 
post-purification of the radiolabelled product will play an important role in the choice of a labelling 
method. The use of 68Ge/68Ga-generators known with high levels of germanium breakthrough and 
metal impurities may limit a kit-based approach.  
 
Limitations  
The ITLC method utilized during quality control analyses could not distinguish between colloidal 
impurity and the labelled compound. Although final purification was performed using a C18 SEP-
PAK cartridge, ITLC could not confirm if all colloidal impurities are indeed removed during this 
step. It has been reported, for 68Ga-peptide synthesis, that C18 purification will lead to the removal 
of colloidal impurities [43]. 
Further investigation of the labelled product to clearly characterise the origin of the double peak 
seen on the HPLC chromatogram, to exclude the possible formation of impurities would also be 
valuable.   
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We did not investigate and develop an automated method using pre-purification with a PS-H+ 
cartridge and HEPES as buffering agent. It is therefore not known if the HEPES content would also 
exceed pharmacopoeial accepted limits as observed with the fractional elution method. 
In this study, a standard peptide quantity of 50 µg NOTA-UBI (100 µg in the study investigating 
scavengers using method 2) and in varying buffer volumes was used for all labelling experiments. 
The effect of standardising peptide concentration but using different volumes of buffer on labelling 
parameters was not investigated.  
The use of L-methionine as a radical scavenger to improve radiochemical purity was not 
investigated.  
Total synthesis time was 39 - 41 minutes and 43 - 45 minutes for the fractional elution and pre-
purification methods respectively. The additional pre-purification step increased total synthesis time 
by 4 - 5 min. Flow rates used after the heating step were based on the published manual method. 
Faster flow rates were not investigated during this study.  
The flow rate in the following post-heating steps can influence total synthesis time: 
• Adsorption of labelled [68Ga]Ga-NOTA-UBI on the C18 cartridge. 
• Washing of the C18 cartridge with PBS. 
• Desorption of labelled [68Ga]Ga-NOTA-UBI from the C18 cartridge. 
It is therefore possible that total synthesis time can be reduced by increasing the flow rates in the 
post-heating steps. Shorter synthesis time will also lead to an increase in the amount of radiolabelled 
product. 
Despite a longer total synthesis time, the pre-purification method using a cationic exchange cartridge 
still has the benefit of ensuring that metallic impurities are removed prior to the labelling step. 
Furthermore, an automated synthesis method has the added benefit of producing [68Ga]Ga-NOTA-
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UBI with a high degree of consistency and robustness, satisfying GMP requirements for the 
production of radiopharmaceuticals.   
 
Conclusion 
Three different fully automated methods for the labelling of [68Ga]Ga-NOTA-UBI have been 
successfully developed and tested. The use of radical scavengers to reduce radiochemical impurities 
was successfully introduced in method 2 and 3. Both the fractional elution and pre-purification 
methods can be used for the synthesis of [68Ga]Ga-NOTA-UBI under GMP compliant conditions. 
This study confirms that automated synthesis methods have the benefit that radiopharmaceuticals 
are produced in a robust and reproducible manner. 
The availability of a PET radiopharmaceutical such as [68Ga]Ga-NOTA-UBI, that can be 
synthesised using an automated synthesis module, is expected to positively contribute to the medical 
management of patients with infections.  
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Three automated labelling methods for gallium-68 ubiquicidin were succesfully developed. Two 
methods were further optimized using radical scavengers to reduce the fomation of radiolytic 
impurities. These methods were proven to be suitable for the routine production of this 






The effect of radical scavengers on the radiolabelling characteristics of  
gallium-68 ubiquicidin 
 
Rationale for research covered in this chapter 
Radical scavengers are often used to increase the radiochemical purity of radiopharmaceuticals. 
These radical scavengers can reduce the formation of radiolytic impurities caused by radiolysis 
and oxidation of the methionine group of methionine containing peptides.  
Gallium-68 ubiquicidin (29-41) is an example of a methionine containing peptide. It is evident 
from the experimental work conducted in the previous chapter that there was a clear indication for 
the use radical scavengers to reduce radiolytic impurities. In this chapter the impact of several 
commonly used radical scavengers on the labelling characteristics of gallium-68 ubiquicidin is 
evaluated and discussed.  
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Radical scavengers have been widely used to reduce radiolysis in the labelling of 
radiopharmaceuticals. The purpose of this study was to evaluate the effectiveness of several 
commonly used scavengers in the labelling of [68Ga]Ga-NOTA-UBI. We also compare our results 
with recent reports that have shown an increased interest in the use of ethanol as a scavenger and its 
beneficial effect on several labelling characteristics for some gallium-68 compounds. Results from 
our study indicate that, for [68Ga]Ga-NOTA-UBI, a combination of at least two scavengers is 
required to reduce radiolysis to an acceptable level and render a final labelled product with a 
radiochemical purity ≥ 95%. 
 
Introduction 
Recent years have seen an unprecedented growth in the use of gallium-68 (68Ga) for the labelling of 
radiopharmaceuticals for research and clinical application. The introduction of reliable 68Ge/68Ga- 
generators significantly contributed to this growth because a major advantage of using a generator 
lies in the on-demand availability of a positron emitting radionuclide such as 68Ga without the need 
of an on-site cyclotron.1,2  
Since 68Ge/68Ga-generators became commercially available, many 68Ga-labelled 
radiopharmaceuticals have been successfully introduced into clinical practice.2–7 68Ga-labelled 
DOTA-TATE, DOTA-NOC and PSMA are but a few that have had a major effect in the clinical 
handling of  cancers such as neuro-endocrine tumours and prostate cancer.8–11 
Ubiquicidin (29-41) is a fragment of an antimicrobial peptide that can be labelled with 68Ga and is 
investigated as an agent for imaging infections using PET.12–16 Recently we reported on development 
of an automated synthesis method for the labelling of 68Ga-ubiquicidin (29-41) (Figure 3.1).17 Initial 
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development and testing of an automated synthesis method revealed the formation of an impurity 
most likely caused by radiolysis.  
 
Figure 3.16The chemical structure of [68Ga]Ga-NOTA-UBI (29-41)  
 
Radiolysis is dependent on factors like total radioactivity concentration and the chemical structure 
of the radiopharmaceutical.18 The high positron emitting fraction (maximum energy: 1.92 MeV and 
mean energy: 0.89 MeV) of 68Ga may be responsible for an increased risk of radiolysis.10 The 
presence of the hydroperoxyl and hydroxyl free radicals (•OOH and •OH) is caused by high energy  
β-particles emitted by 68Ga.10 When high levels of radioactivity are used for radiolabelling, 
radiolysis cannot always be prevented without the use of free radical scavengers. This may be 
especially important when 68Ga is produced using a cyclotron.19–22 Peptides containing methionine, 
such as ubiquicidin (TGRAKRRMQYNRR) and gastrin, seem to be especially prone to radiolysis. 
During synthesis, auto-oxidation to sulphoxides is a common occurrence.23 
The use of radical scavengers has been well described. 10,24–30 Ascorbic acid, ethanol, gentisic acid 
and L-methionine have all been suggested as scavengers to improve radiochemical purity.30,31 Other 
less commonly used scavengers include sodium thiosulphate, sodium nitrate and sodium iodide.28 
The use of formic acid combined with a scavenger such as ascorbic acid has also been described.32 
Improved radiolabelling of [68Ga]Ga-DOTA-TOC by the addition of ethanol to the labelling mixture 
has recently been reported.33 Besides an improvement in radiochemical purity by reducing 
radiolysis, it also significantly improved radiochemical yield. These studies have shown that 
increasing the ethanol content of the labelling mixture from 0 - 30% (v/v) when using only 10 µg 
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DOTA-TOC precursor as opposed to 50 µg recommended by the manufacturer, resulted in an 
increase in radiochemical yield from 24% to 96% at 70 °C. The use of ethanol to improve 
radiolabelling with automated synthesis modules has also been demonstrated by Meisenheimer et 
al. They report using ethanol in increased concentrations of 10 - 40% or 0 - 30% (v/v), which led to 
an increase in RCP, yield and specific activity of [68Ga]Ga-DOTA-TOC.24 In contrast we found that 
using ethanol (10% v/v) in the radiolabelling of [68Ga]Ga-NOTA-UBI, the radiochemical purity 
(RCP) was well below our acceptance criteria of 95%. 
Previously we reported on the introduction of a cationic pre-purification method for the labelling of 
[68Ga]Ga-NOTA-UBI using an automated synthesis module.17 This method has proven to yield 
metal free 68Ga eluates using a 5 M NaCl solution; however, the average RCP for [68Ga]Ga-NOTA-
UBI was only 65 ± 3% (n = 3). Whilst there were negligible amounts of unchelated 68Ga detected 
with radio-HPLC, unfortunately 33 ± 3% radiolytic impurities were detected in the final product 
solution. The current work demonstrates the effectiveness of well-known scavengers to reduce 




The automated labelling procedures were performed using a Scintomics GRP synthesis module 
(Scintomics, Germany). Freeze-dried 1,4,7-triazacyclononane-1,4,7-triacetic acid ubiquicidin 
(NOTA-UBI) obtained from GL Biochem (China) or ABX (Germany) was dissolved in ultrapure 
water (18.5 Ω) and subdivided in 100 µl aliquots (1 µg/µl) and frozen at −20 °C. 100 µg of frozen 
NOTA-UBI was used for each of the labelling methods.. 68Ga was obtained by eluting a 68Ge/68Ga- 
generator (iThemba LABS, South Africa) with 0.6 M HCl (ABX, Germany). A cationic pre-
purification method with PS-H+ cartridges (ABX, Germany) was used to purify the 68Ga-eluate for 
all labelling procedures. C18 Sep-Pak cartridges (Waters, USA) were pre-conditioned on the 
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synthesis module at the start of the synthesis using 5 ml HPLC-grade ethanol (Merck, USA). Sodium 
acetate buffer (1.0 M) was prepared using sodium acetate trihydrate (Sigma Aldrich, Germany). 
Sodium chloride 0.9% (B. Braun, South Africa) and pharmaceutical grade ethanol (Merck, USA) 
were used to prepare the ethanol/saline (50% v/v) solution. Ultrapure water was freshly prepared 
with a Milli-Q water purification system (Millipore, USA). Ascorbic acid (North East 
Pharmaceutical Group, South Africa), gentisic acid (Merck, USA) and pharmaceutical grade ethanol 
(Merck, USA) were tested as radical scavengers. Ammonium formate (Kimix, South Africa) was 
used to prepare a 1.0 M ammonium formate solution as an alternative to sodium acetate. Sodium 
chloride (5 M) was prepared using pharmaceutical grade sodium chloride (Merck, USA). HPLC 
analyses were carried out using HPLC-grade acetonitrile (Merck, USA) and trifluoroacetic acid 
(Sigma Aldrich, Germany) as mobile phases. 
 
Radiolabelling  
The 68Ge/68Ga-generator eluate pre-processing method was adopted from a method published by 
Martin et al. 34 Briefly, the 68Ge/68Ga-generator was eluted with 10 ml of a 0.6 M HCl solution and 
the eluate was diluted with 8 ml ultrapure water. The entire volume was then slowly passed over a 
PS-H+ cartridge (ABX, Germany) to retain the 68Ga-activity and remove possible metal 
contaminants. Purified 68Ga was recovered from the PS-H+ cartridge using 1.5 ml of a 5.0 M NaCl 
solution. This solution was then transferred into the reaction vessel which contained 100 µg NOTA-
UBI in 1.5 ml of 1.0 M acetate solution along with a radical scavenger or combination of scavengers. 
We used a standard scavenger mass of 5 mg for both ascorbic- and gentisic acid for all labelling 
procedures as suggested by Mueller et al. 31 Table 3.1 presents a summary of the different 
scavengers or combination of scavengers resulting in 5 different radiolabelling methods. All 
mixtures were heated for 10 minutes at 90 °C, cooled for one minute and purified using a C18 Sep-
Pak cartridge as previously described by Ebenhan et al.13 [68Ga]Ga-NOTA-UBI was desorbed from 
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the C18 Sep-Pak cartridge using 2 ml ethanol/saline (50% v/v) and transferred into a sterile vial. 
The final product was further diluted to 15 ml with phosphate buffered saline (PBS) to provide a 
product that would be suitable for intravenous injection.  






Total volume # during 
radiosynthesis 
NOTA-UBI 
concentration   
1 
1 M sodium acetate 
1.5 ml 
1.4% ascorbic acid 
0.350 ml 
3.350 ml 30 µg/ml 
2 
1 M sodium acetate 
1.5 ml 
1.6% gentisic acid 
0.310 ml 
3.310 ml 30 µg/ml 
3 
1 M sodium acetate 
1.5 ml 
ethanol 10% v/v 
0.310 ml 
3.310 ml 30 µg/ml 
4 
1 M sodium acetate 
1.5 ml 
1.4% ascorbic acid, 
ethanol 10% v/v 
0.350 ml; 0.170 ml 
3.520 ml 28 µg/ml 
5 
1 M ammonium formate 
2.0 ml 
1.4% ascorbic acid 
0.350 ml 
3.850 ml 26 µg/ml 
# total volume includes 1.5 ml 5 M NaCl eluant required to desorb 68Ga-activity from PS-H+ cartridge; M = method 
 
Radioanalysis 
Instant thin-layer chromatography (ITLC) 
Instant thin-layer chromatography was performed using the same method as previously described 
by Breeman et al. using a glass microfiber chromatography medium impregnated with silica gel 
(ITLC-SG, Varian, USA).35 The mobile phase consisted of 0.1 M sodium citrate (pH = 5.0). 
Distribution of radioactivity on the strip was determined with a radio-chromatographic scanner 






Radio-HPLC analysis was performed using a Shimadzu Nexera XR HPLC system (Shimadzu, 
Japan) with a variable wavelength PDA UV-detector and a Raytest gamma detector (Raytest, 
Germany). A Waters C18 Symmetry analytical column (4.6 × 250 mm × 4.6 mm × 5 μm, Waters, 
USA) was used as the stationary phase for all analyses. The mobile phase (v/v) for the gradient 
HPLC analyses was 0.1% TFA in ultrapure water and 0.1% TFA in acetonitrile. The flow rate was 
set at 2 ml/min. The retention time (RT) for free gallium-68 and [68Ga]Ga-NOTA-UBI was 2.0 – 
3.0 minutes and 6.0 – 7.0 minutes respectively. Radiolytic impurities eluted either just before or 
after the main peak. 
 
Results and Discussion 
Previous research performed on [68Ga]Ga-NOTA-UBI highlighted the need for the use of a radical 
scavenger to reduce the effect of radiolysis.17 The aim of this study was to evaluate the effect of 
several commonly used scavengers on the radiochemical purity of [68Ga]Ga-NOTA-UBI and their 
effect on radiolysis. Table 3.2 gives a summary of the labelling characteristics for [68Ga]Ga-NOTA-
UBI comparing method 1 to 5 using three commonly used radical scavengers.  
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Table 3.25Comparison of labelling characteristics for [68Ga]Ga-NOTA-UBI using different 
combinations of radical scavengers and buffering solution (n=3) 
 Method 1 Method 2 Method 3 Method 4# Method 5 
Buffer NaOAc† NaOAc† NaOAc† NaOAc† NH4HCO2‡ 
Scavenger  





Generator age (days) 9 ± 1 14 ± 1 7 ± 1 72 ± 6 12  ± 1 
Activity (MBq) 1539 ± 119 1710 ±42 1687 ± 117 1467 ± 85 1740 ± 42 
Radiochemical purity (ITLC) (%) 99.0 ± 0.7 99.4 ± 0.2 99.3 ± 0.2 99.3 ± 0.1 99.0  ± 0.3 
Radiochemical purity (HPLC) (%) 90.7 ± 2.7 85.0 ± 1.5 89.1 ± 1.4 97.3 ± 0.4 90.0 ± 4.8 
Activity yield (MBq)* 600 ± 38.4 830 ± 71.4 141 ± 17.6 580 ± 99.3 799 ± 109.0 
Radiochemical yield (%) 61 ± 5.4 76 ± 7.5 13 ± 1.8 57.3 ± 3.8 72 ± 10.3 
Residual activity on PS-H+ 
(MBq)* 
112 ± 20.5 87.1 ± 3.5 95.9 ± 8.8 129 ± 29.6 
110.7 ± 
16.6 
C18-SPE retained activity (MBq)* 32.3 ± 12.7 22.7 ± 4.4 11.9 ± 7.0 14.2 ± 7.3 12.6 ± 5.9 
C18-SPE retained activity (%) 3.3 ± 1.4 2.1 ± 0.2 1.1 ± 0.4 2.5 ± 0.6 1.2 ± 0.6 
Notes: AA) ascorbic acid, GA) gentisic acid, EtOH) ethanol 
* measured at the end of the synthesis; C18 SPE – disposable C18 based solid-phase extraction cartridge; PS-H+ - 
disposable cartridge with a strong cation exchange resin 
# data from previous study, time from previous elution/synthesis ≥ 4 h. 
†Sodium acetate; ‡Ammonium formate 
 
It is important to note that radio-ITLC results showed a RCP of > 98% for all labelling methods as 
opposed to a RCP range of 85.0 ± 1.5 - 97.3 ± 3.0 calculated with radio-HPLC. Figure 3.2 represents 




Figure 3.27Representative radio-ITLC chromatogram for quantitative analysis of 
[68Ga]Ga-NOTA-UBI following C18-based purification. Radio-ITLC stationary phase 
ITLC-SG paper; mobile phase: 0.1M sodium citrate (pH 5); Chromatogram region 1: 
[68Ga]Ga-NOTA-UBI; Region 2: detection of possible unchelated 68Ga. 
 
The discrepancy in RCP between radio-HPLC and radio-ITLC occurred because the thin-layer 
paper-based chromatography technique lacked the capability to resolve peaks of [68Ga]Ga-NOTA-
UBI and its closely retained radiolytic impurities. Furthermore, this method35 could not be used to 
detect the presence of any colloidal impurities. These results suggest that radio-ITLC analysis may 
be limited and unreliable to accurately determine the RCP of [68Ga]Ga-NOTA-UBI following our 
radiosynthesis method. 







Figure 3.38Typical radio-HPLC chromatograms of [68Ga]Ga-NOTA-UBI 
demonstrating the impact of different scavengers. #1= free 68Ga; #2 & #4 = radiolytic 
impurities; #3 = [68Ga]Ga-NOTA-UBI, a) ascorbic acid scavenger, b) gentisic acid 
scavenger c) ethanol scavenger d) ascorbic acid and ethanol scavengers e) ascorbic acid 
in ammonium formate buffer 
 
The quantitative analysis of the % RCP of [68Ga]Ga-NOTA-UBI seen on radio-HPLC for each of 
the radiolabelling methods in Figure 3.3 is outlined in Table 3.  
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Table 3.36Summary of peak quantification of radio-HPLC chromatograms 
 % Radiochemical purity 




1- Sodium acetate / 1.4% AA 0.1 - 2.1 6.5 - 11.0 86.9 - 93.4 
2- Sodium acetate / 1.6% GA  0.1 - 12.7 4.4 - 13.7 82.8 - 86.3 
3- Sodium acetate /10% EtOH 0.1 - 1.3 9.3 - 12.8 87.7 - 90.7 
4- Sodium acetate / 1.4% AA + 5% EtOH 0.3 - 0.4 1.9 - 2.7 96.9 - 97.8 
5- Ammonium formate / 1.4% AA   0.8 - 1.5  2.7 -13.2 85.3 - 96.5 
Notes: AA) ascorbic acid, GA) gentisic acid, EtOH) ethanol, *) values represent the sum of impurities retaining at 5.0 
min (#1) and 6.1 min (#2). **) percentage radiochemical purity (HPLC; n=3) 
 
Impact of ascorbic acid as scavenger 
There is ample evidence in the literature of the effectiveness of ascorbic acid as a radical scavenger 
on its own or in combination with other scavengers.10,18,21,22,25,31 Our results indicate that, using 
ascorbic acid on its own in the labelling of [68Ga]Ga-NOTA-UBI, radiolysis was not sufficiently 
inhibited. Figure 3.3a represents a typical radio-HPLC chromatogram where ascorbic acid was used 
as scavenger. Impurities seen at retention time ~ 6.1 min on all radio-HPLC chromatograms 
represent on average 8.0 ± 2.1% (n = 3) of total counts.  
The small peak seen at retention time ~ 1.8 min is most likely due to unchelated 68Ga. [68Ga]Ga-
NOTA-UBI eluted at ~ 6.7 minutes. The average RCP on radio-HPLC was 90.7% which is well 
below our in-house criteria of ≥ 95%. Radio-yield was acceptable with an average of 61 ± 5.4%. 
Average unchelated 68Ga and radiolytic impurities were 1.3 ± 0.9 and 8.0 ± 2.1 respectively. Radio-





Impact of gentisic acid as scavenger 
Gentisic acid as the only scavenger did not achieve a RCP ≥ 95% on radio-HPLC. Radio-HPLC 
analyses showed two impurities at retention time (RT) ~ 2.5 and 6.1 min. respectively. The impurity 
at RT at ~ 2.5 min is most probably also due to unchelated 68Ga while the impurity seen at RT ~ 6.1 
min is due to a radiolytic impurity formed during labelling (Figure 3.3b). We noted a relatively high 
presence of unchelated 68Ga in two of the syntheses, despite optimizing the pH to 3.5 – 4.0. 
Interestingly, when no unchelated 68Ga was observed on radio-HPLC, the impurity due to radiolysis 
at RT ~6.1 min increased significantly. It is not clear if there is a correlation between unchelated 
68Ga and formation of radiolytic impurities using gentisic acid as scavenger. 
The presence of relatively high levels of unchelated 68Ga as well as varying levels of radiolytic 
impurities (ranging from 4.4 – 13%) in the labelled product, suggest that gentisic acid on its own is 
not a suitable radical scavenger. The average radio-yield 76 ± 7.5%, the highest of all scavengers 
tested in this study. The average percentage of impurities related to unchelated 68Ga and radiolysis 
were 7.5 ± 5.4% and 7.5 ± 4.4%, respectively. The average RCP was 85 ± 1.5% (n = 3). 
 
Impact of ethanol as scavenger 
The use of ethanol as a scavenger in the labelling of somatostatin analogues such as [68Ga]Ga-
DOTA-TOC, has recently attracted considerable interest. Not only does the addition of ethanol 
increase RCP of this radiopharmaceutical, but it also increases yield. As mentioned elsewhere, 
studies have also shown that it also reduces the peptide mass required for labelling, therefore 
increasing the specific activity of the radiopharmaceutical.  Our work with [68Ga]Ga-NOTA-UBI 
has shown, when ethanol was used in concentrations of 10% v/v during labelling of ubiquicidin, 
radio-yield significantly decreased, despite adjusting the pH to 3.5 – 4.0 with sodium acetate buffer. 
The average yield, using 10% v/v ethanol, decreased to only 13 ± 1.8%. The average RCP was 89.1 
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± 1.4%. Reducing the ethanol content to 5 - 7% (v/v) did improve radio-yield but not radiochemical 
purity. Radio-HPLC analyses (Figure 3.3c) also indicate that most impurities seen on radio-HPLC 
are due to radiolysis with minimal presence of unchelated 68Ga.  A possible additional impurity 
eluting at RT ~ 6.3 min was observed in one of the syntheses.  It is not clear if this impurity is also 
due to radiolysis, but we grouped it together with the radiolytic impurities. Our results indicate that 
ethanol alone did not reduce radiolytic impurities to an acceptable level. Furthermore, we did not 
observe an increase in yield or specific activity as reported by Meisenheimer et al. and Eppard et al. 
for [68Ga]Ga-DOTA-TOC.24,33 The average percentage unchelated 68Ga and radiolytic impurities 
were 0.4 ± 0.6 and 10.5 ± 1.6% respectively.  
The results from this research also suggest that the side products observed on radio-HPLC are more 
likely due to radiolysis and not the result of oxidation of methionine during the heating step. Lower 
activities used in the manual labelling method did not result in the formation of the side products.   
Our findings further suggest that the use of ethanol to reduce radiolysis can be very dependent on 
the type of peptide. 
 
Impact of ascorbic acid and ethanol as combined scavengers 
The best RCP, determined by radio-HPLC, was achieved using a combination of ascorbic acid (5 
mg) and ethanol (5% v/v). Using this combination, the RCP was consistently higher than our in-
house specification of ≥ 95%. The average percentage unchelated 68Ga and radiolytic impurities 
were 0.4 ± 0.05% and 2.4 ± 0.3% respectively (n = 3). 
As can be seen on the radio-HPLC chromatogram (Figure 3.3d), impurities due to radiolysis were 
less than 3% when ascorbic acid and ethanol were used in combination. The presence of unchelated 
68Ga was < 1%. This combination furthermore resulted in acceptable radio-yields of 57 ± 3.8%. The 
average RCP was 97.3 ± 0.4%.  
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Ascorbic acid as scavenger in ammonium formate buffer 
As mentioned earlier, ammonium formate and ascorbic acid have also been successfully used to 
reduce radiolysis using a fractional elution method.17 Ammonium formate is not regularly used as a 
buffer in our institution. However, based on the success to reduce radiolysis in combination with 
ascorbic acid in the fractional elution method, we opted to test this buffer scavenger combination 
using the cationic pre-purification method. Our results indicate that this combination was not 
effective in reducing radiolysis to an acceptable level. Radiochemical impurities seen on radio-
HPLC (Figure 3.3e) were mostly due to radiolysis. Additionally, we observed the presence of 
impurities eluting after the main peak (RT ~ 5.7 min) on two syntheses. The average percentage 
unchelated 68Ga and radiolytic impurities were 1.5 ± 0.6% and 8.5 ± 4.4% respectively (n = 3). 
Radiochemical yield was on average 72 ± 10.3%. 
In summary, the results of this study demonstrated a marked reduction of radiolytic impurities with 
a combination of 1.4% ascorbic and 5% ethanol , therefore an improvement of the RCP for [68Ga]Ga-
NOTA-UBI to meet our in-house release criteria of ≥ 95%. 
Recommendations 
The purpose of this limited study was not to characterize the radiolytic impurities seen on radio-
HPLC. It is, however, possible that our radio-HPLC method was not sufficiently sensitive to resolve 
other impurities close to the main peak. A further investigation into the identification and 
characterization of side-products should be considered, using a similar approach to that adopted by 
Mu et al.36 Our study also did not investigate all possible combinations of scavengers or buffer-
scavenger combinations. This may produce different results in reducing radiolysis. The scavengers 
included in this study are all safe for human administration and do not require additional analytical 
testing post synthesis. Further investigation into a more reliable TLC method for [68Ga]Ga-NOTA-
UBI should also be considered. This may include an investigation into different stationary phases 
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and/or mobile phases similar to the work published by Larenkov and Maruk for [68Ga]Ga-DOTA-
TOC, [68Ga]Ga-DOTA-TATE and [68Ga]Ga-RGD2. 37  
 
Conclusion  
A radical scavenger combination of 1.4% ascorbic acid and ethanol (5% v/v) achieved the best 
results in reducing radiolysis in the labelling of [68Ga]Ga-NOTA-UBI using a pre-purification 
method with 5 M NaCl. Our results also indicate that ethanol on its own was not effective in 
limiting the presence of radiolytic impurities. Increasing the ethanol content to > 5% significantly 
reduced radio-yield. Our results furthermore suggest that the use of ethanol as the only scavenger 
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Radical scavengers were successfully used to decrease the presence of radiolytic impurities during 
the labelling of gallium-68 ubiquicidin. It was necessary is use a combination of two radical 







A comparison of labelling characteristics of manual and automated synthesis 
methods for gallium-68 labelled ubiquicidin 
 
Rationale for the research covered in this chapter 
The advantages of using an automated labelling method, rather than a manual method, were 
extensively discussed in the previous chapters. Automated labelling methods are usually based on 
an optimized manual method used during the development phase of radiopharmaceuticals, but they 
are not merely a scale-up of the original method performed by a piece of equipment.. Besides the 
higher activities used, the ingredients in the labelling reaction can differ. It is therefore important 
to ensure that important labelling characteristics are not negatively affected by the automation 
process.  
In this chapter, the labelling characteristics of a manually prepared product are compared with 
those resulting from two automated methods developed during this research. The important 
similarities and differences in labelling characteristics between the manual and automated methods 
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P 
Highlights 
• Optimized manual and automated synthesis methods for [68Ga]Ga-NOTA-UBI  were 
compared. 
• Automated methods were more robust than a manual method. 
• Operator radiation exposure was considerably less for automated synthesis methods.   
 
Abstract 
Gallium-68 labelled 1,4,7-triazacyclononane-1,4,7-triacetic acid ubiquicidin (NOTA-UBI) is 
currently investigated as a PET radiopharmaceutical for the imaging of infections. The aim of this 
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study was to compare the labelling characteristics of an optimized manual radiosynthesis method 
with those of optimized automated synthesis methods. Data from this study suggest that automated 
radiosynthesis of [68Ga]Ga-NOTA-UBI provides a higher degree of robustness and repeatability 
than the manual method. Our results also suggest that for our full-scale automated synthesis, radical 
scavengers should be considered to reduce radiolysis. Automated synthesis methods have the 
advantage of markedly reducing radiation exposure to operators. Standardised automation also 
makes the synthesis more reliably compliant with Good Manufacturing Practice guidelines. 




The development of synthesis methods for novel radiopharmaceuticals often entails testing of 
different manual radiolabelling procedures on a small scale. Small-scale labelling has the advantage 
that it limits the radiation exposure to the operator (De Decker and Turner, 2011). Initial experiments 
are usually repeated several times to assess the impact of various parameters such as pH, incubation 
temperature and time, type and volume of buffer etc. on the success of the radiosynthesis. 
Optimizing radiometal-based synthesis methods may also include the evaluation of bifunctional 
chelators to determine the best radiometal-chelator-ligand complex. Once optimal labelling 
conditions have been determined and satisfactory results achieved, the next phase typically 
comprises evaluation of the robustness and repeatability of the radiosynthesis evaluation. This phase 
often includes up-scaling the quantity of reagents together with an increase in radioactivity used. 
Scaling-up is required to determine if labelling results can be reproduced using sufficient 
radionuclide for one or more patients. In theory, labelling results obtained from manual labelling 
methods should correlate well with those obtained from automated syntheses.  
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Ubiquicidin 1-59 is a 6.6 kD linear cationic peptide with antimicrobial properties. It has been shown 
to be present in low concentration in various organs such as the colon mucosa, epithelial cells of the 
human airways and also macrophages (Hiemstra et al., 1999; Tollin et al., 2003). It is present intra-
cellularly and only released during acute infection or severe cell damage. Ubiquicidin (UBI) has 
been found to affect a spectrum of pathogens (Brouwer et al., 2006). Various peptide fragments of 
UBI 1-59 have been synthesized, including UBI 1-18, UBI 18-35, UBI 18-29, UBI 29-41 and UBI 
31-38. Brouwer’s study also showed that the synthetic UBI derivatives containing amino acids 29-
41 or 31-38 had the best targeting properties which could possibly be adopted in as a tool for non-
invasive nuclear imaging techniques such as single-photon emission tomography (SPECT) and 
positron emission tomography (PET). Researchers have since then developed a number of 
procedures that can be used for radiolabelling of ubiquicidin fragments (Bhatt et al., 2018, 2017; 
Bhusari et al., 2019; Brouwer et al., 2006; Vilche et al., 2016). Peptide fragments UBI 29-41 and 
UBI 31-38 were successfully labelled with gallium-68 (68Ga) and technetium-99m (99mTc). 
Preclinical investigations in mice by Brouwer et al. have shown that the 99mTc-labelled fragments 
accumulated only in sites of infection. 
There are a number of approaches that can be used in the production of gallium-68 (68Ga) 
radiopharmaceuticals for clinical application (Velikyan, 2015). Automated and semi-automated 
radiosyntheses of 68Ga-radiopharmaceuticals have the advantage of enabling compliance with Good 
Manufacturing Practice (GMP) guidelines (Vis et al., 2015).  
In 2014, synthesis of gallium-68-labelled UBI 29-41 (i.e. [68Ga]Ga-NOTA-UBI) using a manual 
radiolabelling technique was first reported (Ebenhan et al., 2014) and a module-based automated 
radiosynthesis has recently been developed (Le Roux et al., 2020). The use of automated synthesis 
modules to label radiopharmaceuticals with 68Ga has been reported by several authors (Decristoforo, 
2012; Malizia et al., 2012; Schopf et al., 2018; Vis et al., 2015). Well-known buffers such as sodium 
acetate, 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) and formic acid are 
commonly used in 68Ga-labelling (Bauwens et al., 2010; Sasson et al., 2010; Velikyan et al., 2008). 
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Various methods described in the literature compare manual with automated syntheses but to the 
best of our knowledge no head-to-head comparison of a manual synthesis with two automated 
methods for the same radiopharmaceutical exists. The aim of this study was to evaluate how the 
labelling characteristics of a manual synthesis procedure for preparing [68Ga]Ga-NOTA-UBI 
compare to those of two different automated synthesis procedures.  
 
Methods 
Material and Preparations 
Analytical or pharmaceutical grade reagents were used for both manual and automated synthesis 
procedures. Gallium-68 eluates were obtained from a 68Ge/68Ga-generator (iThemba LABS, 
Somerset West, South Africa) using 0.6 M HCl (ABX, Radeberg, Germany). Both the generator and 
the GRP automated synthesis unit (Scintomics, Fürstenfeldbruck, Germany), were housed in a NMC 
Ga-68 hot cell (Tema Sinergie, Faenza, Italy). All disposable material for the synthesis module was 
compliant with GMP standards. The routine preparation and general radiosynthesis protocols using 
a module for the production of [68Ga]Ga-NOTA-UBI were previously reported (Le Roux et al., 
2020). 
Freeze-dried batches of UBI 29-41, conjugated to either 1,4,7,10-tetra-azacyclododecane-1,4,7,10-
tetra-acetic acid (DOTA) or 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) or 1,4,7-
triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), were obtained from GL Biochem 
(Shanghai, China) and stored at -80 °C as 25 µg aliquots suitable for small-scale, manual 
radiolabelling. For the automated methods, 2 mg of NOTA-UBI (ABX, Radeberg, Germany) was 
dissolved in 2.0 ml of ultra-pure water to render a stock solution with a concentration of 1 mg/ml. 
The stock solution was sub-divided in 50 and 100 µl aliquots and frozen at -20 °C. A sodium acetate 
trihydrate (NaOAc) solution (2.5 M) was used as a buffer for manual preparations while 1.0 M 
NaOAc or 1.0 M ammonium formate were used in the automated synthesis methods. Based on initial 
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experiments, aliquots of NOTA-UBI were prepared for up-scaled production at 50 µg (all automated 
syntheses using generator eluate fractionation) and 100 µg (all automated syntheses including eluate 
pre-processing); to meet the criteria for optimal [68Ga]Ga-NOTA-UBI preparation under the 
different radiolabelling conditions. Ascorbic acid and pharmaceutical grade ethanol were obtained 
from North East Pharmaceutical Group (Midrand, South Africa) and Merck (Kenilworth, NJ, USA), 
respectively. PS-H+ cartridges (ABX, Radeberg, Germany) were used for eluate pre-processing. C18 




Manual radiolabelling: Small-scale and up-scaled manual radiosyntheses were used as references, 
adopting the conditions described previously (Ebenhan et al., 2018, 2014) using 68Ge/68Ga-generator 
eluate fractionation. The first set of experiments investigated the 68 Ga-radiolabelling of DOTA-
UBI, NODAGA-UBI and NOTA-UBI to find the most suitable chelator-ligand complex. 
Concentrations (µg/ml) of 4, 8 16, 32, and 64 for each chelator-ligand complex were labelled with 
micro-scale quantities of gallium-68. Briefly, 180 µl of a buffered 68Ga-solution (pH 3.5 - 4.0) was 
added to either of the NOTA-, NODAGA- and DOTA-UBI solution. The labelling mixtures were 
heated for 10 min at 80 °C, followed by a cooling period of 5 min. The scaled-up radiolabelling 
conditions remained the same, however, 2 ml 68Ga-activity was mixed with 50 µg NOTA-UBI. The 
NOTA-UBI concentration of the reference manual labelling was 19.6 µg/ml. 
Automated radiolabelling: Method 1 used fractional generator elution while an eluate pre-
purification step with a strong cationic ion exchanger was used for automated method 2. Importantly, 
both manual and automated methods were optimized for type of buffer used, peptide mass and use 
of radical scavengers, if required. 
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Automated method 1: 68Ge/68Ga-generator eluate fractionation was performed with 0.6 M HCl and 
a 2 ml fraction was used for the synthesis. The pH of the eluate was adjusted to 3.5 - 4.0 using 2.0 
ml of a 1.0 M ammonium formate buffer. The buffered eluate mixture was slowly added to the 
reaction vial containing 50 µg of NOTA-UBI and 350 µl ascorbic acid (1.4%). The NOTA-UBI 
concentration in this labelling mixture was 11.2 µg/ml. The mixture was heated for 10 min at 90°C, 
cooled for one minute and purified using a C18 Sep-Pak cartridge. [68Ga]Ga-NOTA-UBI was 
desorbed from the C18 matrix using a mixture of ethanol/saline (50% v/v) and ultimately filtered 
through a 0.22 µm filter into a sterile vial.  
Automated method 2: The 68Ge/68Ga-generator was eluted with 10 ml 0.6 M HCl. The eluate was 
further diluted to 18 ml with ultra-purified water and slowly passed over a PS-H+ cartridge where 
most of the 68Ga-activity was trapped and purified from co-eluted metals. Subsequently, 1.5 ml of a 
5.0 M NaCl solution was used to desorb the 68Ga-activity from the PS-H+ matrix into a reaction 
vessel containing 100 µg NOTA-UBI buffered in 1.3 ml 1.0 M NaOAc. The reaction vessel also 
contained a radical scavenger combination of 350 µl ascorbic acid 1.4% and 170 µl ethanol. This 
radiolabelling mixture, with a NOTA-UBI concentration of 28.4 µg/ml, was further processed as 
described above in method 1. 
 
Qualitative Analysis 
Radio-high performance liquid chromatography (HPLC) 
Following completion of the automated methods the radiochemical purity (RCP) was determined 
using a Shimadzu Nexera XR HPLC system (Kyoto, Japan), which included a variable wavelength 
photodiode array detector and a gamma detector (Raytest, Straubenhardt, Germany). The analysis 
was performed at a wavelength of 254 nm. The solvent gradient method consisted of mobile phases 
(v/v) A (0.1 % trifluoroacetic acid (TFA) in water) and B (0.1% TFA in acetonitrile) using a Waters 
C18 analytical column (4.6 mm x 250 mm x 5µm) as stationary phase (0 – 2 min: 5% B, 2 - 18 min: 
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65% B, 18 - 24 min: 5% B). The flow rate was set at 2.0 ml/min. The column temperature was kept 
at 40 °C throughout the analysis. The retention time for [68Ga]Ga-NOTA-UBI was 6.0 - 6.9 minutes 
whereas free 68Ga-activity was retained for 1 - 2 minutes. 
 
Radio-instant thin-layer chromatography (ITLC) 
A glass microfiber chromatography strip impregnated with silica gel (ITLC-SG, Varian, USA) was 
used as stationary material. The mobile phase consisted of 0.1 M sodium citrate (pH = 5.0). 
Distribution of radioactivity was determined using a radio-chromatographic scanner (Lablogic, 
Sheffield, United Kingdom) allowing gamma-counting of the full length of the ITLC-SG strip. 
Radiochemical purity was determined by peak analysis (counts-per-minute/area under the curve). 
[68Ga]Ga-NOTA-UBI remained at the origin whereas unchelated 68Ga was separated by migrating 
to the mobile phase front. 
 
Product stability 
Stability at room temperature of [68Ga]Ga-NOTA-UBI prepared by both automated methods was 
assessed following sterile filtration and dilution to 15 ml with phosphate buffered saline. The 
radiochemical purity was determined with radio-ITLC and radio-HPLC analyses at the end of 
synthesis (EOS) and at 180 min after EOS. 
 
Additional quality control measures 
Table 4.1 presents a summary of additional quality control procedures performed after module-




Table 4.17Quality control procedures and release criteria for automated radiosynthesis methods 
Quality control procedure Release criteria Method 
Visual appearance Clear, colourless, particle free Visual inspection 
Radiochemical purity ≥ 95% [68Ga]Ga-NOTA-UBI ITLC / HPLC 
Radionuclidic identity (half-life) 63 – 73 min Dose calibrator 
pH of final product 6.0 – 8.0 pH strips 
Bacterial endotoxins  < 10 EU/ml Endosafe PTS  
Residual ethanol content < 10% v/v Calculation 
Sterile product filtration ≥ 3.45 bar Filter integrity test 
Bacterial growth  Sterile (pass) Broth incubation 
Germanium breakthrough < 0.001 % Dose calibrator 
 
Operator Radiation Exposure  
All radiolabelling techniques were performed using appropriate radiation protection and shielding. 
The guidelines of the European Pharmacopoeia (8.0) were followed for preparation of the 68Ga-
radiopharmaceuticals. The fully-shielded, automated synthesis module was remotely operated. The 
68Ge/68Ga-generators used for this part of the study had a similar age of three months. Operator 
radiation exposure was recorded using an electronic X-ray and gamma personal dosimeter (PM1610, 
Polimaster, Belarus) (energy range of 29 keV – 10 MeV; 0.1 µSv increments) attached to the outside 
of the lab coat. The whole-body radiation dose was determined by recording the dosimeter reading 
at the beginning of the elution until end of synthesis, including mimicking the dispensing of two 




Results and discussion 
Prior to this comparative study, each of the automated synthesis methods was optimized for peptide 
mass, buffer type and volume as well as scavenger addition. This resulted in different NOTA-UBI 
concentrations for the 3 labelling methods. Experimental results during the development of the 
automated synthesis methods showed the formation of a hydrolytic impurity seen on HPLC (data 
not shown) which required the use of an appropriate radical scavenger. The manual radiolabelling 
did not necessitate the use of a scavenger. 
 
Choice of chelator-UBI complex 
The optimal combination of azamacrocyclic chelators (NOTA-NODAGA and DOTA) and UBI was 
identified by gradually decreasing the chelator-UBI concentration during manual radiolabelling to 
4 µg/ml (Figure 4.1). The best % RCP obtained using the NOTA moiety was compared to that of 
NODAGA- and DOTA-UBI (p < 0.05). To determine the optimal labelling concentration that 
yielded a RCP > 90%, chelator-UBI concentrations (µg/ml) of ≥8, ≥16 and ≥ 32 for NOTA-UBI, 
NODAGA-UBI and DOTA-UBI were evaluated. Such a direct comparison has not yet been 
described in the literature, however, experimental work conducted by Guérin et al. also suggested 
the use of NOTA-functionalized peptides for PET imaging (Guérin et al., 2010). Tri-azamacrocyclic 
bifunctional chelators such as NOTA and NODAGA have both been suggested as viable alternatives 
to DOTA based on the formation of thermodynamically stable complex with Ga(III) ions. Maximal 
interaction is achieved due to optimal N3O3 denticity and a smaller ring size than that of DOTA. 





Figure 4.1968Ga-radiosyntheses of UBI conjugated to NOTA, NODAGA or DOTA as 
azamacrocyclic bifunctional chelators (n = 3); radiolabelling was performed in the 
presence of NaOAc, pH 3.5 – 4, at 80 °C for 10 min. The % radiochemical purity was 
determined using ITLC. 
 
A total mass of 25 µg NOTA-UBI was deemed sufficient for an up-scaled manual labelling to 
account for precursor losses due to glassware adherence and possible slower reactivity in the larger 
reaction volume. Table 4.2 summarises the results obtained with the manual synthesis method 
versus the two automated synthesis methods. The 68Ga-activity concentration for the manual 
radiolabelling was 458 - 806 MBq/ml, considered to be an acceptable range of radioactivity for 
radiation protection and efficient dose preparation. For automated methods, the average 68Ga-

























Table 4.28Comparison of the manual reference method with the automated synthesis methods 
 Manual 
radiolabelling 
(n = 9) 
Automated 
method 1 
(n = 3) 
Automated 
method 2 
(n = 3) 
Volume of 68Ga-activity (ml) 1.0 2.0 10.0 
Type of eluate pre-processing  EF EF SCX 
Average starting activity (MBq) 587 ± 149$ 1498 ± 73 1467 ± 85 
Residual radioactivity: PS-H + (%)# - - 8.8 ± 2.0 
Buffering molarity and type 2.5 M NaOAc 1.0 M NH4HCO2 1.0 M NaOAc 
Volume of buffer used (ml) 0.278 2.0 1.5 
Total mass NOTA-UBI (µg) 25 50 100 
Incubation time (min)/  (°C) 10 – 15/ 80 10/ 90 10/ 90 
Radiosynthesis time (min)† 31 ± 7 32 ± 2 38 ± 2 
% Radiochemical yield # 65.5 ± 22.6 63.2 ± 1.5 57.3 ± 3.8 
% radiochemical purity (ITLC) 97.1 ± 1.9 98.9 ± 0.3 99.3 ± 0.1 
% radiochemical purity (HPLC) 97.5 ± 0.8 96.4 ± 0.9 97.3 ± 0.5 
[68Ga]Ga-NOTA-UBI yield (MBq) 473 ± 234 690 ± 22 580 ± 99 
Molar activity (MBq/nmol) 20.4 ± 11.4 27.6 ± 0.9 11.4 ± 1.9 
Retained activity C18 SPE (%) 10.0 ± 8.9 1.6 ± 1.4 2.5 ± 1.5 
Notes: EOS = End of synthesis, NH4HCO2 = ammonium formate; NaOAc = sodium acetate tri-hydrate;  
EF = eluate fractionation; SCX = eluate processing using a strong cationic exchange matrix;  † = time measured from 






The manual method had the shortest radiosynthesis time (31 ± 7 min) while the radiosynthesis time 
for the cationic pre-purification method was the longest (38 ± 2 min). Both automated synthesis 
methods included a 6-minute step to condition the C18 cartridge prior to generator elution (not 
reflected in the synthesis time). The added pre-purification step, which utilizes all eluted 68Ga-
activity, increased the synthesis time by 6 minutes. Pre-purification usually also increases the molar 
activity by decreasing the volume of the labelling mixture. The loss of activity on the PS-H+ cartridge 
was less than 10% of the eluted activity from the generator. Despite this longer synthesis time, it is 
deemed necessary to include this step in the synthesis methods where a 68Ge/68Ga-generator eluate 
with known high levels of metal impurities is used (Chakravarty et al., 2013). It is well-known that 
certain metal impurities such as Zn, Fe and Cu may have a detrimental effect on the synthesis of 
peptides with 68Ga-chloride (Velikyan, 2015).  
The increase in radiosynthesis time resulted in about 10% decrease in radiochemical yield when 
compared to the automated fractional elution method (method 2).  
 
Choice of buffering agent  
Manual synthesis may be susceptible to operator influences such as the speed at which the solvents 
and reagents are introduced during the various synthesis steps or between different syntheses. In the 
automated synthesis methods, reagents and solvents are introduced at pre-programmed speeds in a 
consistent manner. The volume of the eluate and buffer used in the manual method was smaller than 
that used in the automated methods. The buffer volume was intentionally increased and the molarity 
of NaOAc adapted for automation because the synthesis module could not accurately add a volume 
less than 500 μl into the reaction vial. This increase in buffer volume resulted in varying peptide 
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concentrations for the three synthesis methods. Variable peptide concentrations used in the 
automated methods still resulted in acceptable radiochemical purity and yield.  
 
Radiochemical purity  
Experimental results during the development of the automated synthesis methods showed the 
formation of a radiolytic impurity seen on HPLC (data not shown). The average starting 68Ga-
activity for the manual method was 587 ± 149 MBq while for automated methods it was about 2-3 
times higher (1483 ± 81 MBq). The higher 68Ga-activities used in the automated methods made them 
more prone to radiolysis. In order to reduce radiolysis it was necessary to use radical scavengers in 
the automated methods. The addition of radical scavengers successfully reduced the radiolytic 
impurities and increased RCP to ≥ 95%. The manual method did not require the use of a scavenger. 
Besides lower starting activities, differences in peptide mass and volume of labelling mixture may 
have contributed to prevention of radiolysis. Herein, original data is provided, suggesting that the 
radiochemical purity of both automated methods was more robust and repeatable than that observed 
with the manual method. The average percentage radiochemical purity (TLC and HPLC) for both 
the manual and automated procedures was above the required 95%.  
 
Percentage radiochemical yield and losses of product activity 
The manual method resulted in varying radiochemical yields (42 - 89%), amongst others due to 
inconsistency in following the labelling protocol. However, this is not uncommon for manual 
radiosynthesis. The average percentage radiochemical yield of module-based preparations of 
[68Ga]Ga-NOTA-UBI showed a markedly smaller variation (< 4%) than the manual method (22%).  
There was a large difference in the percentage activity retained on the C18 cartridge when the 
manual method is compared to automated methods. The manual method retained 4-5 times more 
activity than the automated methods, despite matching labelling conditions. A possible reason can 
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be that more colloids are formed during the manual method which are retained on the C18 cartridge 
during product purification. It should be noted that the average RCY from all methods was 
satisfactory, providing sufficient radioactivity to potentially prepare one or more patient doses 
despite differences in generator age. 
 
Effect on final product quality and stability 
The molar activity of the different radiosynthesis methods ranged from 11.4 MBq/nmol to 27.6 
MBq/nmol. This wide range of molar activities did not affect the quality of the final product. Radio-
ITLC and radio-HPLC results indicated that [68Ga]Ga-NOTA-UBI, labelled with both automated 
methods, remained stable at room temperature for at least 180 min (data not shown). Unpublished 
data also confirmed that the manually labelled [68Ga]Ga-NOTA-UBI was stable for up to 180 min 
post synthesis.   
 
Radiation exposure to operator 
Radiation exposure to operators is influenced by several factors such as exposure time, shielding 
and distance from the radiation source, as well as the degree of automation of the radiosynthesis. 
Module-based syntheses have a clear advantage over manual methods in this regard. Table 4.3 
provides a summary of radiation exposure readings recorded during manual and module-based 
methods. In general, exposure levels for the manual method were higher despite using a lower 
starting activity (about 60 % less). In order to compare the exposure from manual and automated 
syntheses, we normalised the effective doses to starting activity. The normalized effective dose for 
the automated method was 0.002 µSv/MBq compared to 0.04 µSv/MBq for the manual method. 
This is a 20-fold reduction in radiation exposure. This data confirms the added advantage of 
automation regarding radiation exposure of operators in the day-to-day production of 
radiopharmaceuticals in a clinical setting.  
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Manual 109 ± 7.9 32.2 ± 7.5 25.2 ± 6.2 0.04 ± 0.05 
Automated* 101 ± 51 36.9 2.3 ± 0.4 0.002 ± 0.01 
*) data from method 1 and 2 was combined. 
 
Automated synthesis modules are usually housed in hot cells which also contribute to lower operator 
radiation exposure and lower background radiation. Even without a hot cell, the hands-off set-up is 
the most important reason for the reduced radiation exposure seen with the automated methods, as 
there is no need for the operator to remain in the vicinity of the high radioactivity. It can be argued 
that a major advantage of manual syntheses is the possibility to intervene in the labelling procedure 
if necessary. However, operator intervention makes it more difficult to comply with GMP standards.  
In a scenario where an operator uses the manual labelling method daily, the whole-body effective 
dose could exceed 6 mSv per year. Higher starting activities or manual labelling several times per 
day could lead to a whole-body effective dose close to the annual limit of 20 mSv per year (averaged 
over 5 years) as published by the International Commission for Radiological Protection’s guidance 
for occupational exposure (International Commission on Radiological Protection, 2003). 
Additional quality control and compliance with release criteria  
Pharmacopoeias provide the legal and scientific benchmark for delivering high quality medicines, 
including radiopharmaceuticals. Novel radiopharmaceuticals, such as 68Ga-labelled ubiquicidin, do 
not have pharmacopoeial monographs. This study used the European Pharmacopoeia’s published 
monograph for Gallium (68Ga) Edotreotide Injection as a guide for the addressing release criteria for 
68Ga-labelled ubiquicidin, as the synthesis of these two radiopharmaceuticals are very similar. Both 
automated methods fulfilled our in-house criteria for release of a radiopharmaceutical for human 
administration (Table 4.1). Manual radiolabelling met with the release criteria in three consecutive 
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preparations. Even though it may be generally compliant with GMP, a weakness of the manual 
method is that it is less robust. GMP plays an integral part in the production of radiopharmaceuticals 
intended for clinical use. Consistent and reproducible results produced by automated synthesis 
methods make them the method of choice for producing radiopharmaceuticals in a GMP-compliant 
manner. Batch records produced by the module software are usually GMP-compliant, providing a 
method to monitor labelling steps and conditions. The module software furthermore provides a 
mechanism for reliable traceability of the radiopharmaceutical manufacturing process.  
 
Conclusion  
The aim of this work was to compare the product characteristics and pharmaceutical quality of 
optimized automated and manual methods. 
Our results showed a high degree of robustness and repeatability using a Scintomics GRP synthesis 
unit. It was necessary to include scavengers for both automated methods to reduce radiolysis. 
Automated synthesis methods furthermore have the clear advantage of reducing radiation exposure 
to operators and facilitating production of radiopharmaceuticals in a GMP compliant manner.  
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Summary 
The labelling characteristics of the automated method were more robust and repeatable when 
compared with the manual method. Both automated methods required the use of radical 
scavengers to reduce the formation of radiolytic impurities. This comparison also confirmed the 




Chapter 5  
The use of HEPES-buffer in the production of  
gallium-68 radiopharmaceuticals  
 
Rationale for the research covered in this chapter 
HEPES (4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid) is a zwitterionic buffer that is 
extensively used in the radiolabelling of gallium-68 radiopharmaceuticals to create optimal 
labelling conditions. A pharmacopoeial limit regulates the HEPES content in radiopharmaceutical 
preparations. The limit is strict, and a lack of toxicity is cited as a reason for the strict limit.  
In this chapter, current available data on the toxicity of HEPES in animals and humans are 
presented in the form of technical note. 
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HEPES (4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid) is a buffer that is used in the 
radiolabelling of gallium-68 compounds. The beneficial effects of HEPES on specific activity in 
bioconjugates have been well described. Current strict regulations on the HEPES content in 
radiopharmaceuticals limit its use when intended for parenteral administration.  
This technical note summarizes data from the literature on the toxicity of HEPES in dogs after 
intravenous infusion and the subsequent use in humans. We also highlight the use of HEPES in an 
Unites States Food and Drug Administration (FDA) labelled intravenous drug formulation. 
Regulatory institutions may consider this data to review current strict limits. 
 
Use of HEPES in pharmaceutical products 
Radiosynthesis of gallium-68 compounds requires a labelling mixture with a pH of 3.5 – 5.0 to 
ensure good complexation of gallium-68 with the precursor. Buffers such as 4-(2-hydroxyethyl) 
piperazine-1-ethanesulfonic acid (HEPES) and sodium acetate are extensively used in the labelling 
of radiopharmaceuticals with gallium-68. These buffers are reported to have low metallic 
complexation properties making them suitable to adjust pH during labelling and also reduce 
formation of colloids (Bauwens et al., 2010). 
HEPES, a zwitterionic buffer, is listed as a Good’s buffer with a pKa values of 3.00 and of 7.55 
(Good et al., 1966). Velikyan et al. illustrated the beneficial effect of HEPES on specific activity in 
radiolabelling bioconjugates (Velikyan et al., 2004). A number of references also indicate that 
adjusting the pH with HEPES during radiolabelling with gallium-68 provides the optimum results 
in terms of molecular activity, reproducibility, reliability and versatility (Bauwens et al., 2010; 
Eppard et al., 2014; Pfaff et al., 2018; Velikyan et al., 2004). The European Pharmacopoeia 
prescribes a strict limit for the HEPES content in radiopharmaceuticals intended for intravenous 
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administration (European Pharmacopeia, 2017). However, the method described in the European 
Pharmacopoeia to test for HEPES in radiopharmaceutical preparations has proven to be unreliable 
(Antunes et al., 2020; Pfaff et al., 2018; Sasson et al., 2010). The low limit has hampered the use of 
HEPES in gallium-68 radiopharmaceuticals, despite its superior buffering properties. A lack of acute 
toxicological data, especially after intravenous administration, is generally cited as the main reason 
for these strict limits (Bauwens et al., 2010; European Pharmacopeia, 2017; Sasson et al., 2010).  
A chronic tolerance study of 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (product code 
TVZ-7), published in 1997 by Theodore et al., provides important data on HEPES toxicity in beagle 
dogs after intravenous infusion (Theodore et al., 1997a). The animals were monitored for 
pharmacological or toxicological effects from increasing doses of 5 – 500 mg/kg HEPES 
administered over an extended period of 148 days. Initially doses were administered daily via 
intravenous infusion but then changed to alternate days because of a subjective observation of stress 
at doses reaching 300, 350 and 400 mg/kg. Routine clinical pathology evaluations consisted of 
complete blood count and blood chemistry. Histopathology (bone marrow and liver biopsies) was 
done at the end of the highest dose segment when clinical effects were observed. Important 
observations from the study included the following: 
a) Vomiting, a pharmacological effect of HEPES administration, occurred in the first two 
segments of the study but subsided when HEPES was administered before feeds.  
b) When intravenous (IV) doses approached 400 mg/kg (4000 mg for a dog with an average 
weight of 10 kg), significant changes in the hematopoietic and reticuloendothelial system 
were observed in some dogs. These included hypercellular bone marrow and extramedullary 
hematopoiesis.  
The study however concluded that no severe adverse effects are associated with chronic intravenous 
administration of HEPES in doses ranging from 5 – 500 mg/kg. In a patient with an average weight 
of 70 kg, this would amount to a maximum dose of 35 000 mg (35 g).  
Stellenbosch University https://scholar.sun.ac.za
90 
A more significant publication is the preliminary evaluation of a fixed dose of HEPES in humans 
by Theodore et al. The investigators report on the use of HEPES to evaluate its potential beneficial 
effects in clinical cancer (Theodore et al., 1997b). In this study setup, most subjects received an 
average fixed daily dose of 5000 mg, administered intravenously for 2 weeks. Thereafter, the same 
dose was administered three times per week for 2 more weeks. Patient response was evaluated at 4 
weeks. A maintenance dose of 5000 mg, administered two to three times per week, was thereafter 
instituted. This study reported minimal side-effects and toxicity, similar to what was reported in the 
study with dogs.  
The current limit for HEPES in radiopharmaceutical preparations specified by the European 
Pharmacopoeia is 200 µg/V, where V represents the maximum injected dose in millilitre. This very 
strict limit translates to a maximum HEPES amount of 200 µg per dose. Labelling of specific 
radiopharmaceuticals may require different volumes and concentrations of HEPES as reported by 
Antunes et al. (Antunes et al., 2020). Using these examples, in a worst-case scenario where no 
HEPES is removed during the labelling process, a total single dose between 283 and 714 mg HEPES 
would be intravenously administered to a patient. This translates to a HEPES dose of 4.0 – 10.2 
mg/kg for a 70 kg patient. The highest single dose is much lower than the maximum mg/kg dose 
used in the chronic toxicity study in dogs. This is also approximately 14 % of the average dose 
administered to humans in the preliminary fixed dose study by Theodore et al. It is known that a 
considerable fraction of HEPES is removed during the purification process (Mueller et al., 2012; 
Mukherjee et al., 2015; Pfaff et al., 2018). The HEPES content is therefore significantly lower than 
the doses used in the Theodore toxicity study and still far below the chronic dose of 400 mg/kg 
where significant changes in the hematopoietic and reticuloendothelial systems were observed in 
dogs. 
In 2015 the FDA approved ONIVYDE TM (Merrimack Pharmaceuticals), a topoisomerase 1 inhibitor 
which also contains HEPES as a buffering system. The pharmaceutical formulation contains 4.05 
mg/ml HEPES in a 10 ml vial solution, to be diluted in 500 ml dextrose 5% for intravenous 
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administration (Baker and Levien, 2017; Merrimack, 2015; Theodore et al., 1997a). The 
recommended dosage is 70 mg/m2 Ironectan (4.3 mg/ml) resulting in an average male (1.9 m2) 
receiving a total amount of 133 mg of the drug and 126 mg of HEPES. This amount of administered 
HEPES is much higher than the recommended 200 µg per dose for gallium-68 based 
radiopharmaceuticals. Limiting the HEPES content to 200 µg/V, as advised currently by the 
European Pharmacopoeia, may be a far too strict limit.  
To conclude: The expected HEPES amounts used in radiopharmaceutical preparations is 
significantly less than the amount that was tolerable in other approved pharmaceuticals, in particular 
the HEPES doses given to dogs as part of the chronic toxicity study published by Theodore et al. 
The HEPES levels administered intravenously within a radiotracer formulation is also considerably 
lower than the amount given to cancer patients which was considered safe based on their clinical 
toxicology screening. It is not plausible for patients scheduled for Nuclear Medicine investigations 
to receive a daily intravenous dose of HEPES exceeding 5000 mg, which was well-tolerated in 
humans. Taking all factors into account, regulatory institutions may consider reviewing the strict 
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_______________________________________________________________________________ 
Summary 
Available data suggest that the current pharmacopoeial limit for HEPES may be too strict. The 
HEPES content in radiopharmaceuticals preparation is far lower than the doses administered in 
animals and also much lower than the doses used in the human studies. The data presented in can 
be used by regulatory institutions to reconsider the current strict limit. 
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Chapter 6  
Thin-layer chromatography for instant analysis of the radiochemical purity of 
gallium-68 labelled ubiquicidin 
Background 
Quality control of radiopharmaceuticals is a critical step in the production of radiopharmaceuticals 
intended for clinical application. Radiopharmaceuticals must be tested for acceptable quality against 
a set of criteria prior to administration in humans [1, 2]. The synthesis and formulation process of 
gallium-68 radiopharmaceuticals must adhere to certain specifications for physiological 
acceptability, chemical and radiochemical characteristics, as well as product sterility and purity [3]. 
Most PET radiopharmaceuticals have a relatively short half-life and it is important to perform quality 
control within a short time to establish if the labelled product complies with the release criteria. 
However, it is not always possible to complete all quality control tests before injecting the 
radiopharmaceutical to patients. For example, the confirmation of sterility of the 
radiopharmaceutical will only be available after an incubation period of 14 days. Typical tests that 
are performed in the quality control of radiopharmaceuticals include the following [4]: 
• Test for appearance 
• Test for pH 
• Test for bacterial endotoxins 
• Test for filter integrity 
• Test for sterility 
• Test for radiochemical purity (TLC and HPLC) 
• Test for radionuclide purity 
Quality control of [68Ga]Ga-NOTA-UBI was extensively investigated and discussed in this 
study[17]. The finished product was subjected to several quality control procedures to establish if 
the radiopharmaceutical complied with the in-house release criteria. Results from these tests showed 
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that [68Ga]Ga-NOTA-UBI complied with the set of in-house criteria, but from this work it was clear 
that a thin-layer chromatography (TLC) method to identify gallium-68 colloids in the labelled 
product required further investigation.  
TLC is regarded as a fast and effective method to determine the radiochemical purity of 
radiopharmaceuticals [5]. The advantage of TLC is that the analysis can be completed in a relatively 
short time, which is important when dealing with radiopharmaceuticals with short half-lives. This 
method also does not result in large quantities of solvent waste that need to be disposed of. TLC or 
instant thin-layer chromatography (iTLC) to determine the radiochemical purity of gallium-68 
radiopharmaceuticals usually comprises of a two-strip method. The iTLC method used in the 
analysis of gallium-68 labelled DOTA-NOC serves as a good example [6, 7]. This method uses 
iTLC-SG together with the following mobile phases to separate the labelled product from possible 
radioactive impurities:  
• 0.1 M HCl or 0.1 M sodium citrate buffer (pH 5.0) to separate free gallium from colloid and 
labelled compound (free gallium-68 migrates to the solvent front while colloidal impurities 
and the labelled product remain at the origin) 
• A mixture of 1.0 M ammonium acetate/methanol (50:50 v/v) to separate colloidal impurities 
and free gallium from the labelled product (colloidal impurities and free gallium-68 remain 
at the origin while labelled product migrate with the solvent front) 
Silica-gel based iTLC (iTLC-SG) paper (in combination with specific mobile phases) is the 
predominately used stationary phase to distinguish between radiochemical impurities in peptide-
based labelling of gallium-68 radiopharmaceuticals like [68Ga]Ga-DOTA-TATE, [68Ga]Ga-DOTA-
CP04 and gallium-68 labeled exedin [8–10]. Larenkov and Maruk reported the use of a single strip 




iTLC-SG was also used in our analysis of [68Ga]Ga-NOTA-UBI as free gallium can be detected 
with a sodium citrate mobile phase. This method has been extensively validated at our institution 
(data not shown). A typical chromatogram of this method can be seen in Figure 2.3, Chapter 2. The 
presence of gallium-colloids in [68Ga]Ga-NOTA-UBI could not be detected with the ammonium 
acetate/methanol with iTLC-SG strip combination. As the gallium-68 colloidal impurities remain at 
the origin with this method, and the labelled product had a retardation factor (Rf) of 0 - 0.1, 
distinction between the different species was not possible. A typical example of such a 
chromatogram is presented in Figure 6.1 in the results section of this chapter. Adapting the 
combination of the mobile phase to ratios of 70/30 (v/v) and 30/70 (v/v) still did not result in a 
significant change in the Rf of [68Ga]Ga-NOTA-UBI. 
According to Decristoforo et al., a final C18 purification step after radiolabelling of gallium-68 
peptides removed colloidal impurities from the labelling mixture [12]. The two automated synthesis 
methods developed for labelling ubiquicidin with gallium-68 both made use of a C18 purification 
step [17]. The preparation of gallium-68 radiopharmaceuticals from cold kits is becoming more 
widely used and has the advantage that there is no need for the use of an automated synthesis module. 
This can reduce production costs considerably and is therefore an attractive alternative to meet 
routine demand for radiopharmaceuticals. To reduce radiation exposure to the operator, some 
institutions may also opt to omit a C18 purification step after using a kit-based radiolabelling 
procedure. For instance, the instructions for NETSPOT®, a cold kit for the preparation of gallim-68 
DOTA-TATE injections, does not mention a C18 purification step as part of the procedure [13]. 
Recently, a kit-based labelling method for gallium-68 ubiquicidin was published by Bhusari et al. 
[14]. This method does not include a C18 purification step but, like most radiopharmaceutical 
syntheses, did include a final filtration step using a 0.22 µm pore size membrane filter. It is not clear 
if this step is supposed to remove colloidal impurities from the labelling mixture. In the labelling of 
fragments of NODAGA-ubiquicidin with gallium-68, Bhatt et al. specifically mention the use of a 
0.22 µm pore size filter to remove colloidal impurities from the labelling mixture [15]. It should be 
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noted that particles smaller than the filter pores will probably not be removed from the labelling 
mixture by filtration. The TLC method used by Bhatt et al. consisted of a mobile phase of 15% HCl 
in methanol to detect the presence of colloidal impurities and 0.1 M sodium citrate pH 5.0 to detect 
free gallium in the analysis of gallium-68 labelled NODAGA ubiquicidin [15]. ITLC-SG or 
Whatman 3 MM paper was used as stationary phase in both instances. Gallium-68 colloid is 
normally retained in the liver and can influence diagnostic accuracy of the investigation [16]. 
Institutions that decide not to include a post labeling purification, should ensure that a reliable quality 
control procedure exists to detect and accurately quantify colloidal impurities if present in the final 
product. TLC methods are often used for this purpose. 
 
Problem statement 
TLC methods may not be capable to distinguish between all impurities present in 
radiopharmaceutical preparations in all instances. In addition, a TLC method developed for a 
specific compound may not always be suitable for other products labelled with the same 
radionuclide. In the TLC analysis of [68Ga]Ga-NOTA-UBI, the combination of a mobile phase of 
methanol and ammonium acetate (50:50 v/v) with iTLC-SG as stationary phase could not separate 
colloidal impurities from the labelled product. There is thus a need for a method that allows 




The aim of this research was to find a suitable TLC method for gallium-68 ubiquicidin that can 
separate colloidal impurities from the labelled product. This work therefore aimed to: 
1. Assess several mobile phases in combination with iTLG-SG to identify a method that can 
distinguish between gallium-68 colloidal impurities and the labelled product on one TLC 
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strip. In this scenario, colloidal impurities would usually remain at the origin while the 
labelled products should migrate away from the origin.  
2. Establish if C18 purification and membrane filtration (0.22 µm pore size membrane) on 




Prior to testing the combination of specific stationary and mobile phases, an ‘impurity’ mixture was 
first assessed using a known method that can distinguish between free gallium-68 and colloidal 
gallium-68 [8]. This investigation focused on using iTLC-SG (Varian, Lake Forest, USA) strips. 
The following reagents, consumables, chromatography mobile phases, and instruments were used: 
sodium citrate, ammonium acetate, methanol, tri-fluoro-acetic acid, ethyl-acetate, acetone (Sigma 
Aldrich, St Louis, USA), concentrated HCl, acetonitrile, butan-2-one, pH strips with 0.5 unit 
increments, 0.22 µm sterile vented filter (Merck, Massachusetts, USA), saline (B. Braun, 
Melsungen, Germany), sterile empty glass vials (GE Healthcare, Chicago, USA), 0.6 M HCl (ABX, 
Radeberg, Germany), iThemba LABS 68Ge/68Ga-generator (iThemba LABS, Somerset West, South 
Africa), Scan-RAMTM radio-TLC scanner (Lablogic, Sheffield, UK). C18 (tC short) Sep-Pak 
cartridges (Waters, Milford, USA), and a Curiementor 3 dose calibrator (PTW, Germany). Double 
deionized water was obtained from a Merck-Millipore Direct Q3 water purification system (Merck, 
Massachusetts, USA), 
To create an impurity mixture that contained both free gallium-68 and colloidal gallium-68, a 
68Ge/68Ga-generator was eluted with 0.6 M HCl. The eluate (1 ml) was transferred into a separate 
sterile empty glass vial. The pH of this solution was adjusted to pH 6.0 – 6.5 with 2.5 M sodium 
acetate solution, to induce the formation of colloids according to the method suggested by Petrik et 
al. [16]. The mixture was incubated at room temperature for 15 minutes. To confirm the presence 
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of free- and colloidal gallium-68, iTLC-SG strips (85 mm x 8.5 mm) were used for TLC analyses. 
The mobile phase was prepared by diluting 3.4  ml HCl (37% m/m) to 10 ml with analytical grade 
methanol (15% HCl in methanol). Approximately 5 µl of the impurity mixture was spotted at 15 
mm from the lower edge of the strip (origin), which was then immediately placed in a mobile phase 
consisting of sodium citrate buffer pH 5.0. The mobile phase was allowed to migrate up to 5 mm 
from the top edge of the strip (solvent front) and was immediately removed from the developing 
chamber. The strip was dried and distribution of the radioactivity along the strip was visualized 
using a radio-TLC scanner. The background and visible peaks on the resultant radio-TLC 
chromatogram were evaluated. Free gallium-68 migrated with the solvent front while colloidal 
gallium-68 remained close to the origin.  
NOTA-UBI was labelled with gallium-68 as previously described using a Scintomics automated 
synthesis module [17]. The radiochemical purity evaluation with HPLC confirmed the presence of 
> 95% [68Ga]Ga-NOTA-UBI after radiolabelling. Pre-conditioning of the C18 cartridge was 
performed with 5 ml ethanol, followed by 10 ml purified water.  
A series of experiments were conducted to address each of the aims listed earlier: 
Experiment 1 to address Aim 1 
To find a suitable TLC method to identify the presence of colloids in gallium-68 ubiquicidin a 
number of sub-experiments were conducted which included the following: 
Experiment 1.1 
This experiment consisted of evaluating several mobile phases using [68Ga]Ga-NOTA-UBI to 
establish the retardation factor (Rf) of the labelled product on iTLC-SG as the stationary phase. This 
experiment was performed as an initial screening test, to identify a potential suitable TLC method 
where the Rf of [68Ga]Ga-NOTA-UBI was approximately 0.5 – 1.0. Any colloidal impurity would 




In this investigation an impurity mixture that contained both gallium-68 colloids and free gallium-
68 was tested using several mobile phases with iTLC-SG. The purpose of this experiment was to 
find a mobile phase that could successfully distinguish between gallium-68 colloids and free 
gallium-68. Based on the results of this experiment, only mobile phases that could distinguish 
between these two species were considered for further evaluation in experiment 1.3. 
Experiment 1.3 
In this set of experiments, [68Ga]Ga-NOTA-UBI was spiked with a colloid/free gallium-68-
containing impurity mixture (prepared as described earlier) and analyzed with iTLC-SG. Mobile 
phases identified in experiment 1.2 were used.  
Experiment 2 to address Aim 2 
The impurity mixture containing gallium-68 colloids was prepared and the presence of radioactive 
colloids was confirmed as described above. This mixture (1 ml) was passed over a pre-conditioned 
C18 cartridge and the purified effluent was collected in a glass vial. The cartridge was further rinsed 
with 5 ml purified water, which was collected in the same vial. TLC analysis was then performed 
on the combined effluent to identify the presence of colloids using iTLC-SG as stationary phase and 
0.1 M sodium citrate buffer pH 5.0 as mobile phase. On three occasions, the C18 cartridge was 
further washed with 2 ml Milli-Q water and this wash water was collected in a glass vial for further 
TLC analysis.  
To evaluate the effectiveness of membrane filtration to remove colloidal impurities, 1 ml of the same 
eluate mixture used above was passed through a 0.22 µm pore size membrane filter. The filter was 
then rinsed with 5 ml purified water. The filtered mixture was collected in glass vial and analyzed 





The results from experiment 1.1 to 1.3 are listed in Tables 6.1 – 6.3 below. Typical chromatograms 
of TLC analyses performed on the eluate mixture and [68Ga]Ga-NOTA-UBI using iTLC-SG in 
combination with the different mobile phases are shown in Figure 6.1 a-e below. 
Results experiment 1.1 
Table 6.1 Retardation factor [68Ga]Ga-NOTA-UBI using thin-layer chromatography in 
combination with various mobile phases and iTLC-SG as stationary phase 
Mobile phase Rf of [68Ga]Ga-NOTA-UBI # 
Ammonium acetate/ methanol (50:50 v/v) 0.1 - 0.3 
Ammonium acetate/methanol (30:70 v/v) 0 - 0.1 
Ammonium acetate /methanol (70:30 v/v) 0.2 
HCl (conc)/methanol (5:95 v/v) 0 - 0.1 
HCl (conc)/methanol (10:90 v/v) 0 - 0.1 
3% Tri-fluoro acetic acid 0 - 0.1 
4% Tri-fluoroacetic acid 0 - 0.1 
5% Tri-fluoro acetic acid 0 - 0.1 
15% HCl in methanol 0.65 † 
†: well-defined peak shape   
# purified using C18 cartridge 
 
Based on the results displayed in Table 6.1 [68Ga]Ga-NOTA-UBI 29-41 only migrated clearly 
beyond the origin in 15% HCl in methanol on iTLC-SG as stationary phase and formed a 
characteristic peak with a Rf = 0.65 (n = 2). In all other tested mobile phases, there was almost no 
migration of [68Ga]Ga-NOTA-UBI from the origin (Rf 0 – 0.3). 
Results from experiment 1.2 
The results from these experiments displayed in Table 6.2 showed that only 15% HCl in methanol 
and 4% TFA are mobile phases that potentially distinguish between colloidal impurities and free 
gallium-68, however, no colloidal impurities could be detected. The control confirmed the presence 
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of both gallium-68 species and provided an appropriate separation of free gallium-68 from colloidal 
gallium-68. 
Table 6.2 Results from TLC analysis of impurity mixture in various mobile phases on iTLC-SG 
Mobile phase Impurities 
separated (Y/N) 
Rf of separated impurities 
0.1 M Sodium citrate pH 5 buffer (control) Yes Colloid: Rf = 0 – 0.1 
Free gallium-68: Rf = 0.70 
Ammonium acetate methanol (50:50 v/v) No  
Butane-2 one/ethyl acetate (50:50 v/v) No  
Water/methanol (50:50 v/v) No  
Ethyl acetate No  
HCl pH 5 No  
Butane-2 one No  
Acetone No  
Methanol No  
Methanol/saline (50:50 v/v) No  
Methanol saline ( 5:1) No  
Methanol saline (1:5) No  
Saline No  
4% TFA Yes Colloid: not detected 
Free gallium-68: Rf = 0.70 
Acetonitrile /water  (50:50 v/v) No  
15% HCl in methanol Yes Colloid: not detected 
Free gallium-68: Rf = 0.65 
 
Results from experiment 1.3 
Table 6.3 Rf values of [68Ga]Ga-NOTA-UBI using citrate buffer and 15% HCl in methanol 
Product Mobile phase Rf 
Impurity mixture 0.1 M Sodium citrate pH 5.0 coll: 0 - 0.1, free: 0.70 
Impurity mixture 15% HCl in methanol coll: nd, free: 0.70 
[68Ga]Ga-NOTA-UBI 15% HCl in methanol [68Ga]Ga-NOTA-UBI: 0.65 
[68Ga]Ga-NOTA-UBI (sp) 15% HCl in methanol Coll: nd,[68Ga]Ga-NOTA-UBI: 0.65 
[68Ga]Ga-NOTA-UBI 0.1 M sodium citrate pH 5.0 # [68Ga]Ga-NOTA-UBI: 0 - 0.1 
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Figures 6.1a-e Chromatograms of the impurity mixture and [68Ga]Ga-NOTA-UBI with iTLC-SG 
and different mobile phases. In these figures the Y-axis represents the measured radioactivity 
(counts) and the X-axis represents the migration distance (0-100 mm). 
 
Figure 6.1b Typical chromatogram of [68Ga]Ga-
NOTA-UBI using iTLC-SG and 15% HCl in 
methanol 
Figure 6.1c TLC chromatogram of impurity 
mixture using iTLC SG and sodium citrate (Region 
1 = gallium-68 colloids; region 2 = free gallium-68) 
Figure 6.1a Typical chromatogram of [68Ga]Ga-
NOTA-UBI using iTLC-SG and ammonium 
acetate/methanol (50:50 v/v) 
Figure 6.1d TLC chromatogram of impurity 
mixture using iTLG-SG and 15% HCl in 
methanol (region 1 = gallium-68 colloids, 
region 2 = free gallium-68) 
Figure 6.1e Typical TLC chromatogram of 
[68Ga]Ga-NOTA-UBI spiked with the prepared 
impurity mixture using iTLC-SG and HCl in 
methanol (region 1 = [68Ga]Ga-NOTA-UBI) 
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The results from this experiment confirmed that a mobile phase consisting of 15% HCl in methanol 
was not able to detect the colloidal impurities in a spiked sample of [68Ga]Ga-NOTA-UBI. 
Results from experiment 2 
Results of the TLC analyses performed on the mixture which were purified using a C18 cartridge or 
a membrane filter are listed in Table 6.4 below.  
Table 6.4 Results from iTLC-SG analysis of impurity mixture following C18 purification and 
membrane filtration (mobile phase = 0.1 M sodium citrate buffer pH 5) 
Sample (impurity mixture) Colloidal gallium-68 (%) 
Crude (control, n = 3)  9.46 ± 1.93 
C18 SPE purification (n = 5) 4.62 ± 0.37  
Membrane filtration 0.22 µm (n = 4) 4.93 ± 2.06 
 
Both techniques, i.e. C18 purification and membrane filtration, reduced the amount of colloidal 
gallium-68 by 2-fold which was significant compared to the crude (unprocessed) samples. A 





The 15% HCl in methanol was the only mobile phase in which [68Ga]Ga-NOTA-UBI migrated a 
significant distance from the origin on iTLC-SG; it therefore has potential to distinguish between 
gallium-68 colloids and labelled product (Figure 6.2). If present, any gallium-68 colloidal impurity 
would remain at the origin. A single strip TLC method using 4% TFA and iTLC-SG suggested by 
Larenkov and Maruk was not further investigated as the Rf of [68Ga]Ga-NOTA-UBI (Rf = 0.1 - 0.2) 
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was too close to that of colloidal impurities. Altering the TFA contents to 3% and 5% did not result 
in any significant changes in the Rf of [68Ga]Ga-NOTA-UBI.  
Experiment 1.2  
In this experimental setup mobile phases such as 15% HCl in methanol and 4% TFA showed 
potential to separate gallium-68 colloids from free gallium-68 using iTLC-SG as the stationary 
phase. With all these mobile phases, free gallium-68 clearly migrated almost to the solvent front, 
similar to its behaviour in sodium citrate (control, Figure 6.3). Gallium-68 colloids were expected 
to remain at the origin. However, TLC analyses detected very little, and in some cases, no gallium-
68 colloids with the 15% HCl in methanol mobile phase. This observation was made despite the 
confirmed presence of gallium-68 colloids in the mixture. It is important to note that the same 
impurity mixture was used for chromatography with sodium citrate and 15% HCl in methanol. The 
chromatogram in Figure 6.4 shows the presence of small amounts of a colloidal impurity, which is 
markedly less than what was detected when sodium citrate was used as the mobile phase. In certain 
cases, no colloidal impurities could be detected (data not shown). The results from these experiments 
suggest that the higher acidity of 15% HCl in methanol (pH < 2.5) (compared to pH 5.0 for sodium 
citrate) probably dissolves most of the colloidal impurities present in a sample. The pH of 15% HCl 
in methanol solution falls within the pH range where insoluble Ga(OH)3 can become soluble again, 
therefore dissolving any colloidal impurities in the test solution. The presence of colloidal impurities 
can therefore not be detected, making this method unreliable and not suitable for routine use.  
Experiment 1.3 
Based on findings from experiments 1.1 and 1.2 it was a plausible validation step to spike [68Ga]Ga-
NOTA-UBI with the eluate mixture that contained both radioactive impurities. Analyzing the TLC 
chromatogram of spiked [68Ga]Ga-NOTA-UBI using 15% HCl in methanol and iTLC-SG, any 
colloidal gallium-68 impurities should be visible at the origin while [68Ga]Ga-NOTA-UBI (and free 
gallium-68) should migrate with the mobile phase. The TLC chromatogram of the spiked [68Ga]Ga-
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NOTA-UBI sample showed no presence of colloidal gallium-68 at the origin (Figure 6.5). 
[68Ga]Ga-NOTA-UBI (and free gallium-68) migrated a significant distance (Rf = 0.7) as expected, 
confirming what was demonstrated in experiments 1.1 and 1.2. Overall, the results suggest that a 
mobile phase consisting of 15% HCl in methanol can therefore not be used to identify or quantify 
the presence of colloidal impurities in [68Ga]Ga-NOTA-UBI preparations. 
 
Experiment 2 
It is known from the chemistry of gallium that insoluble Ga(OH)3 is formed at a pH range of 3 – 9 
[18]. Under acid conditions, Ga3+ is stable in an aqueous solution, but at a pH range of 3 - 9 insoluble 
Ga(OH)3  may be present in the solution as a colloidal impurity. According Morgat et. al. this 
insoluble species can occur up to pH 9. At pH > 9.5, formation of a soluble gallate ion Ga(OH)4 is 
induced [18]. Labelling of radiopharmaceuticals with gallium-68 using bifunctional chelators such 
as DOTA is predominantly performed at a pH range of 3.5 - 5.0. At this pH range, insoluble gallium-
68 can form when the labelling requires high specific activities, i.e. when the amount of precursor 
is low [10, 19]. Peptide labelling, rather than colloid formation, is enhanced in the presence of higher 
precursor amounts. It is therefore important to test for the presence of gallium-68 colloids in the 
final product solution.  
It has been widely accepted that C18 purification will remove colloidal impurities [12, 20]. In kit-
based formulations of gallium-68 radiopharmaceuticals, C18 purification often does not form part 
of the preparation of the radiopharmaceutical. Results from this study however indicate that a C18 
purification procedure does not remove all colloidal impurities from the product solution after the 
initial purification step. Using TLC analysis, the gallium-68 colloids present in the effluent after 
purification amounted to 4.6 ± 0.4%. This is 48.8% of the amount of colloidal impurities initially 
present in the impurity mixture. Moreover, it should be stated that C18 purification usually consists 
of two steps. In the first step, the labelled product is retained on the C18 cartridge while soluble 
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hydrophilic impurities are diverted to waste. During this step, smaller colloids that are not retained 
by the C18 cartridge will be collected in waste. Subsequent elution of the labelled product from the 
C18 cartridge will most likely not contain any colloidal impurities. It is important to note that the 
experimental set-up in this study was different to that of a normal radiosynthesis. In this experiment, 
the rinse liquid was analyzed as opposed to analyzing the final product as in a normal synthesis.  
Sterilization of gallium-68 radiopharmaceuticals is usually performed using a sterile 0.22 µm pore 
size membrane filter. The use of membrane filtration to remove colloidal impurities is suggested by 
Bhatt et al. To the best of our knowledge, membrane filtration to remove colloidal impurities, has 
not been proven in the literature. TLC analysis of a test solution known to contain colloidal 
impurities showed that the filtered solution still contained colloidal impurities after membrane 
filtration. The gallium-68 colloids present in the solution amounted to 4.9 ± 2.1% of the activity on 
the strip. This value represents 52.1% of the amount of colloidal impurities that was initially present 
in the eluate mixture. Compared to data described by Bhatt et al., the result presented in this study 
demonstrates that membrane filtration is not an effective technique to remove colloidal impurities 
from gallium-68 labelled radiopharmaceuticals. The results rather suggest that C18 purification may 
be a more effective way of removing colloidal impurities from a solution. The results of this study 
also differ from the results reported by Decristoforo et al. in which only 14% reduction in colloidal 
impurities in [68Ga]Ga-DOTA-TOC was achieved with C18 purification step [12]. It should be 
emphasized that our research intentionally created a solution that contained colloidal impurities. It 
is therefore possible that the quantity and size of colloids may differ from normal gallium-68 
labelling procedures.  
 
Conclusion 
Despite testing several mobile phases on iTLC-SG, a reliable method to identify and quantify 
gallium-68 colloidal impurities could not be established. The frequently used mobile phase 
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consisting of a 1 M ammonium acetate/methanol (50:50) mixture cannot distinguish between 
gallium-68 colloids and [68Ga]Ga-NOTA-UBI. Using 15% HCl in methanol as the mobile phase 
may underestimate of the amount of colloids present in a final product solution. This study has 
emphasized the relevance of a C18 purification step in the absence of a suitable method to test for 
gallium-68 colloids in certain gallium-68 radiopharmaceuticals such as [68Ga]Ga-NOTA-UBI. 
Future work should be aimed at identifying a reliable and sensitive method that can quantify the 
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Discussion and Conclusion 
Radiopharmacies situated in relatively small clinical environments such as Nuclear Medicine 
departments usually have limited access to sophisticated equipment in contrast to research and 
manufacturing pharmacies. This can limit access to newer radiopharmaceuticals that are not 
commercially available. This study investigated the in-house synthesis and analysis [68Ga]Ga-
NOTA-UBI as a first model peptide using fairly limited equipment.  
Several important findings are reported in this study. A number of recommendations for future 
research are provided.  
 
Summary of findings 
The achievements of this study can be summarized as follows: 
• Two different fully automated methods for the labelling of [68Ga]Ga-NOTA-UBI have been 
successfully developed, optimized and validated. These methods can both be used for the 
efficient and safe synthesis of [68Ga]Ga-NOTA-UBI under GMP-compliant conditions.  
• The reduction of radiolytic impurities using radical scavengers during the labelling process 
was a key aspect for both automated methods. In particular, following cationic eluate pre-
purification, a combination of at least two radical scavengers were required to reduce the 
formation of radiolytic impurities to an acceptable level. This work also revealed, contrary 
to recent reports in the literature regarding other gallium-68 labelled peptides, that using 
ethanol as a sole scavenger did not improve radiochemical yield or radiochemical purity of 
[68Ga]Ga-NOTA-UBI preparations. The results from this research also suggest that the side 
products observed on radio-HPLC are more likely due to radiolysis and not the result of 
oxidation of methionine during the heating step. Lower activities used in the manual labelling 
method did not result in the formation of the side products.  
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• The in-depth comparison of a manual labelling method with two automated methods for 
[68Ga]Ga-NOTA-UBI supported the automated methods using a Scintomics GRP synthesis 
unit. Those methods showed a high degree of robustness and repeatability and furthermore 
had the clear advantage of reducing radiation exposure to operators and facilitating 
production of radiopharmaceuticals in a GMP-compliant manner.  
• It is evident from data available in the literature that the toxicity of HEPES to humans and 
animals may be overestimated. Clearly, the quantities of HEPES used in the labelling of 
gallium-68 radiopharmaceuticals are far less than the HEPES doses described in published 
studies. It is therefore reasonable to argue that regulatory institutions should reconsider the 
current strict limits. 
• The importance of a reliable and sensitive method to detect the presence of gallium-68 
colloids in [68Ga]Ga-NOTA-UBI preparations is highlighted. This work also emphasizes the 
importance of a purification step to routinely minimize the potential occurrence of gallium-
68 colloids in gallium-68 radiopharmaceuticals such as [68Ga]Ga-NOTA-UBI. This work 
may also be relevant to other radiolabelled peptides.  
 
Limitations and future work 
A few limitations of this study were identified and are listed below. Suggestions for further work 
are provided. 
• The scope of this study did not include [68Ga]Ga-NOTA-UBI synthesis with an automated 
method which combined a generator eluate pre-purification step with HEPES as buffering 
agent.  
• It is possible that the radio-HPLC method that was used in the analysis of [68Ga]Ga-NOTA-
UBI was not sufficiently sensitive to resolve possible product related impurities close to the 
main peak. A further investigation aiming to better identify by-products should be 
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considered. This could ideally form part of a radioanalytical study based on the findings of 
this work. 
• It is not feasible to investigate all possible combinations of scavengers or buffer-scavenger 
combinations, but the tested scavengers showed success. Other combinations than those 
described may also reduce radiolysis and further improve the peptide labelling conditions. 
• The possibility of reducing total synthesis time by increasing the flow rates in the post-
heating steps during the automated labelling of [68Ga]Ga-NOTA-UBI was not investigated. 
It is recommended to investigate further optimization of the synthesis, which may lead to an 
increase in the amount of radiolabelled product. 
• The ITLC method used for quality control analyses of [68Ga]Ga-NOTA-UBI could not 
distinguish between colloidal impurity and the labelled compound. This study only 
investigated iTLC-SG as the stationary phase and other stationary phases should also be 
evaluated. It is recommended that a reliable and sensitive TLC procedure be developed.  
The influence of varying the pH and temperature on the labelling characteristics of [68Ga]Ga-NOTA-
UBI was extensively investigated by Ebenhan et al. during the development of the manual labelling 
method. It was not deemed necessary to reinvestigate these parameters for the purpose of this study. 
A graphical presentation of the effect of varying pH, temperature and incubation time on labelling 
efficiency of [68Ga]Ga-NOTA-UBI is provided in addendum I. 
The findings in this research can be translated to the development of other radiopharmaceuticals 
using alternative chelators and radionuclides for e.g. zirconium-89 (89Zr) and copper-64 (64Cu). This 
may include an investigation into finding the most suitable chelator for the specific radionuclide, 
choice of a buffer to adjust the pH of the labelling mixture, whether heating is required or not, and  
if necessary, considering the use radical scavengers to improve the RCP of the labelled product.   
Labelling monoclonal antibodies with zirconium-89 can be used as example. It is well known that 
antibodies are heat sensitive and the labelling should therefore not include a heating step which can 
damage the antibodies. A further aspect to consider is the choice of a suitable chelator. 
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Desferrioxamine B (DFO) is a hexadentate chelator and the octadentate derivative has been 
suggested as a suitable chelator for labelling with zirconium-89 due to the oxiphilic properties of the 
Zr4+ metal ion [1]. The longer half-life of zirconium-89 (t½ = 78 hours) is suitable for imaging 
radiolabelled antibodies because of their slower pharmacokinetics. Copper-64 on the other hand has 
a shorter half-life (t½ = 12.7 hours) than zirconium-89 and has also been successfully used in 
labelling [64Cu]Cu-DOTA-TATE for somatostatin receptor imaging.  
UBI fragments are cation-rich and in-vitro and pre-clinical studies have shown preferential binding 
to bacterial cells. This radiopharmaceutical is considered to be non-toxic and unlikely to cause 
adverse effects.  First in human studies were encouraging, confirming its potential usefulness as a 
radiopharmaceutical for infection imaging [2]. There has been rapid development in the field of 
infection imaging with an emphasis on distinction between infections and sterile inflammation, and 
also targeting specific properties of bacteria and fungi as a method to detect specific bacterial or 
fungal infections.  
The use of radiolabelled polysaccharides with fluorine-18 has also attracted some interest [3]. A 
transport mechanism for the transport of maltose and maltodextrins that is specific to bacteria has 
made it possible to image bacterial infections using maltose labelled fluorine-18. The potential of 
labelling polysaccharides with gallium-68 is therefore also a possibility due to the chemical 
properties of Ga (III).  
Siderophore-based imaging of A. fumigatus is based on radiolabelling of fusarine C and a tri-
acetylated derivative triacetylfusarine C (TAFC) which are secreted by this fungus. A specific 
siderophore iron transporter (SIT) type is responsible for transport of the chelator complex into the 
fungus [4]. These transporters appear to be confined to fungi only and in certain instances limited to 
specific species.  Specific imaging of P. aeruginosa infection can be achieved by labelling 
pyoverdine (PVD) with gallium-68. Pseudomonas species are known to exclusively produce PVD. 
[68Ga]Ga-PVD has been successfully used to image P. aeruginosa infections even in the presence 
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of a low bacterial burden. This radiopharmaceutical has also shown high specificity and sensitivity 
to detect Pseudomonas infections [4]. These radiopharmaceuticals however still need translation 
into clinical practice.  
A recent systematic review by Auletta et al. discussed several PET radiopharmaceuticals for specific 
bacterial imaging. This review  specifically mentioned that both [68Ga]Ga-NOTA-UBI 29-41 as well 
as [68Ga]Ga-NOTA-UBI 31-38 have been already been used in human studies with promising results 
[5]. Other PET radiopharmaceuticals that have also been used in humans include iodine-124 labelled  
1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodouracil ([124I]FIAU, but this radiopharmaceutical 
was neither specific nor sensitive to identify active bacterial infections [6]. Studies in humans with 
fluorine-18 labelled fluorodeoxysorbitol [18F]FDS were able to distinguish between bacterial 
infections and sterile inflammation [7]. [68Ga]Ga-NOTA-UBI 29-41 is a promising candidate in a 
small group of radiopharmaceuticals investigated for infection imaging with PET. 
 
Conclusion 
Two different automated labelling methods for [68Ga]Ga-NOTA-UBI were successfully developed 
in a hospital radiopharmacy environment using the synthesis module that is routinely used for 
production of [68Ga]Ga-DOTA-NOC and [68Ga]Ga-PSMA. In our institution, pre-purification of 
gallium-68 eluates prior to a radiosynthesis is preferred. It was therefore considered important to 
optimize one of the labelling methods to accommodate this step as part of the production method.  
The effect of scavengers to reduce radiolysis can only be evaluated using HPLC analysis. It is 
therefore important that radiopharmacies that aim to develop new radiolabelling protocols have 
access to HPLC at least during the developmental stage of new protocols. This study highlights 
which steps in the production protocol need to be optimized. Not only does this include optimization 
of the labelling method, but it also involves evaluation of quality control procedures such as thin-
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layer chromatography. It is also essential that information on GMP-compliant methods is discussed 
to provide guidance on the safe production of radiopharmaceuticals for human use.  
The knowledge gained from this study can be used as an important starting point for future 
optimization of production methods of other radiopharmaceuticals at our institution. This study may 
serve as an important guide to other radiopharmacies based in clinical settings regarding successful 
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Figure C1 Typical Scintomics module set-up for a fractional elution labelling method. 
 
Figure C2 Simplified steps of the fractional elution method labelling method. 
50 µg NOTA-UBI 






Figure D1 Typical Scintomics module set-up for a cationic pre-purification labelling method. 
 
Figure D2 Simplified steps of a cationic pre-purification labelling method.  
100 µg NOTA-UBI 
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Effect of varying incubation temperature, pH, incubation duration and compound molarity on the 
labelling efficiency of [68Ga]Ga-NOTA-UBI 29-41 and [68Ga]Ga-NOTA-UBI 30-41 
 
Figure I1 The effects of various factors of 68Ga-labelling for NOTA-UBI including a) sodium 
acetate buffer molarity, b) incubation temperature, c) incubation duration and d) NOTA-peptide 
concentration (n > 3) (reprinted with permission from Ebenhan et al, 2014, ©Elsevier 2014). 
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